[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 4372
1. Chadrawar S, George M, Al-Akraa M, Herber M, Buscombe J: Myocardial uptake of Tc-99m HDP in a patient with prostate carcinoma. Nucl Med Rev Cent East Eur; 2009;12(2):78-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this case report we present an unusual appearance of myocardial uptake of Tc-99m HDP in a 59-year-old renal transplant patient who was imaged while looking for metastases from adenocarcinoma of the prostate.
  • Subsequent investigation demonstrated no obvious cause for this appearance, such as myocardial disease or metastatic cancer.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20235058.001).
  • [ISSN] 1506-9680
  • [Journal-full-title] Nuclear medicine review. Central & Eastern Europe
  • [ISO-abbreviation] Nucl Med Rev Cent East Eur
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 72945-61-0 / technetium Tc 99m hydroxymethylene diphosphonate; X89XV46R07 / Technetium Tc 99m Medronate
  • [Number-of-references] 16
  •  go-up   go-down


2. Duprez R, Lebas P, Marc OS, Mongeois E, Emy P, Michenet P: Preoperative US-guided hook-needle insertion in recurrent lymph nodes of papillary thyroid cancer: a help for the surgeon. Eur J Radiol; 2010 Jan;73(1):40-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These lymph nodes were identified by ultrasound imaging and their metastatic nature was confirmed by fine needle aspiration cytology and measurement of in situ thyroglobulin.
  • RESULTS AND CONCLUSION: In all 8 patients, the suspicious lymph nodes were removed and their metastatic nature was confirmed by the final pathological examination.
  • [MeSH-major] Adenocarcinoma, Papillary / diagnosis. Adenocarcinoma, Papillary / secondary. Biopsy, Needle / methods. Neoplasm Recurrence, Local / prevention & control. Sentinel Lymph Node Biopsy / methods. Thyroid Neoplasms / diagnosis. Ultrasonography / methods


3. Mariani P, Lae M, Degeorges A, Cacheux W, Lappartient E, Margogne A, Pierga JY, Girre V, Mignot L, Falcou MC, Salmon RJ, Delattre O, De Cremoux P: Concordant analysis of KRAS status in primary colon carcinoma and matched metastasis. Anticancer Res; 2010 Oct;30(10):4229-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • KRAS somatic mutations are the main predictive factor for non response to EGFR-targeted monoclonal antibodies in metastatic colorectal cancer (mCRC) patients.
  • A concordance of 97% between primaries and metastatic sites was observed.
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Neoplasms / genetics. Genes, ras. Mutation

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21036746.001).
  • [ISSN] 1791-7530
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  •  go-up   go-down


Advertisement
4. Check JH, Dix E, Sansoucie L, Check D: Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report. Anticancer Res; 2009 May;29(5):1611-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mifepristone may halt progression of extensively metastatic human adenocarcinoma of the colon - case report.
  • Though the metastatic lesions did not disappear, no new ones appeared for a long time and the ones present did not grow.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colonic Neoplasms / drug therapy. Mifepristone / therapeutic use

  • Hazardous Substances Data Bank. MIFEPRISTONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19443374.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 320T6RNW1F / Mifepristone
  •  go-up   go-down


5. Kim JG, Ryoo BY, Park YH, Kim BS, Kim TY, Im YH, Kang YK: Prognostic factors for survival of patients with advanced gastric cancer treated with cisplatin-based chemotherapy. Cancer Chemother Pharmacol; 2008 Feb;61(2):301-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: The present study evaluated baseline patient- or tumor-related prognostic factors in patients with advanced gastric adenocarcinoma.
  • PATIENTS AND METHODS: A total of 304 consecutive patients with newly diagnosed metastatic or recurrent gastric cancer treated with one or more cycles of cisplatin-based chemotherapy at the Korea Cancer Center Hospital were enrolled in the current study.
  • Five independent prognostic factors were identified by a multivariate analysis: poor performance status (hazard ratio [HR], 1.46; 95% CI, 1.32-2.92), elevated total bilirubin (HR, 2.04; 95% CI, 1.73-2.35), presence of peritoneal metastasis (HR, 1.73; 95% CI, 1.57-1.90), presence of bone metastasis (HR, 3.11; 95% CI, 2.69-3.53), and more than 1 metastatic site (HR, 1.22; 95% CI, 1.06-1.38).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / therapeutic use. Cisplatin / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17429626.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


6. Kumar PV, Shirazi M, Salehi M: A diagnostic pitfall of fine needle aspiration cytology in testicular papillary serous cyst adenoma: a case report. Acta Cytol; 2009 Jul-Aug;53(4):467-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic papillary adenocarcinoma was suspected based on FNAB cytology.

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19697740.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


7. Mesa H, Rawal A, Rezcallah A, Iwamoto C, Niehans GA, Druck P, Gupta P: "Burned out" testicular seminoma presenting as a primary gastric malignancy. Int J Clin Oncol; 2009 Feb;14(1):74-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast to primary gastric adenocarcinomas, germ cell tumors are potentially curable even when metastatic.
  • This case describes the radiological and pathological features that helped differentiate this rare situation from the much more common gastric adenocarcinoma, and extends the diagnostic possibilities that must be considered in patients presenting with gastric ulcers.
  • [MeSH-major] Adenocarcinoma / diagnosis. Neoplasms, Unknown Primary. Seminoma / secondary. Stomach Neoplasms / secondary. Testicular Neoplasms / pathology

  • Genetic Alliance. consumer health - Seminoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2003 Apr 15;97(8):1869-75 [12673712.001]
  • [Cites] Histopathology. 2006 Sep;49(3):290-7 [16918976.001]
  • [Cites] JAMA. 1974 Aug 12;229(7):825-6 [4407823.001]
  • [Cites] Prog Urol. 1996 Apr;6(2):278-81 [8777424.001]
  • [Cites] Schweiz Med Wochenschr. 1999 Feb 13;129(6):235-40 [10093882.001]
  • [Cites] Actas Urol Esp. 1999 Nov-Dec;23(10):880-4 [10670132.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1596-600 [2311070.001]
  • [Cites] J Clin Gastroenterol. 1981;3 Suppl 1:35-7 [7328295.001]
  • [Cites] Br J Radiol. 2004 Dec;77(924):1000-6 [15569641.001]
  • [Cites] Acta Chir Scand. 1972;138(7):739-42 [4642714.001]
  • [Cites] Cancer. 2003 Jan 1;97(1):63-70 [12491506.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1412-8 [12954581.001]
  • [Cites] Am J Dig Dis. 1975 Oct;20(10 ):903-13 [1190198.001]
  • [Cites] J Ultrasound Med. 2003 May;22(5):515-21 [12751863.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1977 Dec 29;377(1):67-78 [146949.001]
  • [Cites] Eur J Cancer. 1998 Feb;34(3):353-8 [9640221.001]
  • [Cites] Virchows Arch A Pathol Anat Histol. 1974;363(2):97-112 [4852993.001]
  • [Cites] Int J Urol. 2005 Jan;12(1):115-6 [15661068.001]
  • [Cites] Eur J Surg Oncol. 1992 Apr;18(2):191-4 [1582512.001]
  • [Cites] Clin Transl Oncol. 2005 Nov;7(10):458-63 [16373055.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1287-93 [9552027.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):121-4 [11863093.001]
  • [Cites] Clin Radiol. 1987 Jan;38(1):63-5 [3816068.001]
  • [Cites] Orv Hetil. 1985 Sep 29;126(39):2409-10 [4047643.001]
  • [Cites] Ann Oncol. 1992 Apr;3(4):283-9 [1327076.001]
  • [Cites] BJU Int. 2004 Jul;94(1):74-8 [15217435.001]
  • (PMID = 19225929.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 6PLQ3CP4P3 / Etoposide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; ICE protocol 1
  •  go-up   go-down


8. Kim JH, Kim JH, Yu YS, Kim DH, Min BH, Kim KW: Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma. Oncol Rep; 2007 Dec;18(6):1373-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In spite of recent advances in the treatment of retinoblastoma, chemotherapy is still challenging in high-stage intraocular retinoblastoma or metastatic retinoblastoma.
  • [MeSH-minor] Adenocarcinoma. Argininosuccinate Synthase / genetics. Argininosuccinate Synthase / metabolism. Breast Neoplasms. Cell Division. Cell Line, Tumor. Cell Survival. Eye Enucleation. Eye Neoplasms / enzymology. Eye Neoplasms / pathology. Eye Neoplasms / surgery. Female. Humans. Recombinant Proteins / therapeutic use. Retinoblastoma / enzymology. Retinoblastoma / pathology. Retinoblastoma / surgery

  • Genetic Alliance. consumer health - Retinoblastoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17982619.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 94ZLA3W45F / Arginine; EC 3.- / Hydrolases; EC 3.5.3.6 / arginine deiminase; EC 6.3.4.5 / Argininosuccinate Synthase
  •  go-up   go-down


9. Tanaka S, Saito K, Ito T, Tajima K, Mogi A, Shitara Y, Sano T, Kuwano H: CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens. Oncol Rep; 2007 Jul;18(1):87-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CDX2 as a useful marker of colorectal adenocarcinoma metastases to lung in pre-operative biopsy specimens.
  • Although distinguishing metastatic colorectal adenocarcinoma from primary lung adenocarcinoma is often difficult, pre- or intra-operative identification is very important, as the resection areas for each diagnosis differ substantially.
  • CDX2, a recently cloned homeobox gene, represents a highly specific and sensitive marker of colorectal adenocarcinoma.
  • The study examined 50 consecutive colorectal adenocarcinoma metastases to the lung, including 20 biopsy specimens and 66 resected specimens, and 21 primary lung adenocarcinomas.
  • If CDX2 immunostaining had not been performed, 8 biopsy specimens (40%), and 20 resected specimens (30.3%) might have been diagnosed as equivocal cases either as primary lung cancer or metastatic colorectal cancer, using other markers.
  • These results suggest that positive CDX2 staining represents a highly sensitive and specific marker of metastatic colorectal carcinoma in both biopsy and resected specimens, and is superior to staining for the CK7-/20+ phenotype.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Homeodomain Proteins / metabolism. Lung Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17549351.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 68238-35-7 / Keratins
  •  go-up   go-down


10. Wilkinson N, Scott-Conner CE: Surgical therapy for colorectal adenocarcinoma. Gastroenterol Clin North Am; 2008 Mar;37(1):253-67, ix
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical therapy for colorectal adenocarcinoma.
  • Locally advanced rectal cancer, node-positive colon cancer, and metastatic disease still compose a significant proportion of colon and rectal cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colorectal Neoplasms / surgery. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18313549.001).
  • [ISSN] 0889-8553
  • [Journal-full-title] Gastroenterology clinics of North America
  • [ISO-abbreviation] Gastroenterol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 22
  •  go-up   go-down


11. Verhoef C, van der Pool AE, Nuyttens JJ, Planting AS, Eggermont AM, de Wilt JH: The "liver-first approach" for patients with locally advanced rectal cancer and synchronous liver metastases. Dis Colon Rectum; 2009 Jan;52(1):23-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It allows most patients to undergo curative resections of both metastatic and primary disease and can avoid useless rectal surgery in patients with incurable metastatic disease.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Rectal Neoplasms / pathology

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Rectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19273952.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Bachmann J, Michalski CW, Bergmann F, Büchler MW, Kleeff J, Friess H: Metastasis of rectal adenocarcinoma to the pancreas. Two case reports and a review of the literature. JOP; 2007;8(2):214-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of rectal adenocarcinoma to the pancreas. Two case reports and a review of the literature.
  • CONCLUSION: In patients with a history of a malignant tumor, a newly diagnosed mass in the pancreas--although rare--should raise the suspicion of metastatic disease.
  • [MeSH-major] Adenocarcinoma / secondary. Pancreatic Neoplasms / secondary. Rectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17356246.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 103
  •  go-up   go-down


13. Capizzello A, Tsekeris PG, Pakos EE, Papathanasopoulou V, Pitouli EJ: Adjuvant chemo-radiotherapy in patients with gastric cancer. Indian J Cancer; 2006 Oct-Dec;43(4):174-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • AIM: In this study, we report our experience with adjuvant chemotherapy and radiotherapy in patients with non-metastatic gastric cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17192689.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Abiatari I, Kleeff J, Li J, Felix K, Büchler MW, Friess H: Hsulf-1 regulates growth and invasion of pancreatic cancer cells. J Clin Pathol; 2006 Oct;59(10):1052-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro overexpression of this enzyme in pancreatic cancer cells decreases responsiveness to fibroblastic growth factor-2, as Hsulf-1 is up regulated in primary pancreatic adenocarcinoma.
  • In human primary pancreatic cancers there was strong staining for sulphated HSPGs, which was markedly reduced in metastatic tissue samples.
  • [MeSH-major] Adenocarcinoma / pathology. Neoplasm Proteins / physiology. Pancreatic Neoplasms / pathology. Sulfotransferases / physiology

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 1.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 1997 May 9;272(19):12415-21 [9139688.001]
  • [Cites] J Biol Chem. 1997 Apr 4;272(14):9457-63 [9083085.001]
  • [Cites] J Clin Invest. 1998 Nov 1;102(9):1662-73 [9802880.001]
  • [Cites] Pancreas. 1999 Oct;19(3):281-8 [10505759.001]
  • [Cites] Development. 2004 Dec;131(24):6009-21 [15563523.001]
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Mol Cancer. 2005;4(1):14 [15817123.001]
  • [Cites] J Biol Chem. 2005 Dec 2;280(48):40066-73 [16192265.001]
  • [Cites] Annu Rev Biochem. 1999;68:729-77 [10872465.001]
  • [Cites] Int J Cancer. 2000 Oct 1;88(1):12-20 [10962434.001]
  • [Cites] Teratog Carcinog Mutagen. 2001;21(1):27-44 [11135319.001]
  • [Cites] J Biol Chem. 2002 Dec 20;277(51):49175-85 [12368295.001]
  • [Cites] J Biol Chem. 2003 Jun 20;278(25):23107-17 [12686563.001]
  • [Cites] Gastroenterology. 2004 Jan;126(1):231-48 [14699503.001]
  • [Cites] Oncogene. 2004 Feb 19;23(7):1439-47 [14973553.001]
  • [Cites] Lancet. 2004 Mar 27;363(9414):1049-57 [15051286.001]
  • [Cites] J Biol Chem. 1989 May 15;264(14):7950-6 [2524477.001]
  • [Cites] FASEB J. 1993 Aug;7(11):1023-30 [8370471.001]
  • [Cites] J Cell Biol. 1993 Nov;123(3):513-22 [8227122.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5077-83 [7890615.001]
  • [Cites] Methods Enzymol. 1994;245:219-40 [7760735.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 1995 Oct;15(10):1680-7 [7583544.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Jan;7(1):25-41 [9443985.001]
  • (PMID = 16603650.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 2.8.2.- / SULF1 protein, human; EC 2.8.2.- / Sulfotransferases
  • [Other-IDs] NLM/ PMC1861743
  •  go-up   go-down


15. Kaur G, Ismail R, Harun H: Metastatic mucinous carcinoma of the eyelid. Malays J Pathol; 2005 Dec;27(2):117-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic mucinous carcinoma of the eyelid.
  • Metastatic eyelid tumours are rare and account for less than 2% of all eyelid neoplasms.
  • We report a case of metastatic breast carcinoma to the eyelid in a 60-year-old Chinese lady presenting with a 2-year history of enlarging, painless nodular lower eyelid swelling.
  • We highlight this case to create awareness among clinicians and opthalmologists on the possibility of metastatic disease as a cause of eyelid swelling, especially in patients with a history of cancer.
  • It may also be the first sign of metastatic disease of an internal malignancy.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Breast Neoplasms / pathology. Carcinoma, Ductal, Breast / secondary. Eyelid Neoplasms / secondary

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17191395.001).
  • [ISSN] 0126-8635
  • [Journal-full-title] The Malaysian journal of pathology
  • [ISO-abbreviation] Malays J Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Malaysia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Receptors, Estrogen
  •  go-up   go-down


16. Kundranda MN, Muslimani A, Daw HA, Spiro TP: Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal. Clin Genitourin Cancer; 2007 Sep;5(6):401-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete remission of metastatic carcinoma of the prostate with bicalutamide withdrawal.
  • His initial prostate-specific antigen (PSA) level was 965 ng/dL, and he demonstrated extensive metastatic disease of the thoracic spine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Androgen Antagonists / administration & dosage. Anilides / administration & dosage. Nitriles / administration & dosage. Prostatic Neoplasms / drug therapy. Tosyl Compounds / administration & dosage

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. BICALUTAMIDE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17956714.001).
  • [ISSN] 1558-7673
  • [Journal-full-title] Clinical genitourinary cancer
  • [ISO-abbreviation] Clin Genitourin Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Anilides; 0 / Nitriles; 0 / Tosyl Compounds; A0Z3NAU9DP / bicalutamide; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


17. Spivey KA, Banyard J, Solis LM, Wistuba II, Barletta JA, Gandhi L, Feldman HA, Rodig SJ, Chirieac LR, Zetter BR: Collagen XXIII: a potential biomarker for the detection of primary and recurrent non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev; 2010 May;19(5):1362-72
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Collagen XXIII is a transmembrane collagen previously shown to be upregulated in metastatic prostate cancer.

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 AACR
  • [Cites] Ann Intern Med. 2004 May 4;140(9):740-53 [15126259.001]
  • [Cites] J Biol Chem. 2003 Jun 6;278(23):20989-94 [12644459.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5361-6 [15328173.001]
  • [Cites] Br J Cancer. 1997;75(10):1509-14 [9166946.001]
  • [Cites] Cancer Res. 1998 Apr 1;58(7):1395-9 [9537238.001]
  • [Cites] Lancet. 1999 Jun 5;353(9168):1930-3 [10371572.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):257-62 [16231326.001]
  • [Cites] Oncology (Williston Park). 2005 Nov;19(13):1724-30; discussion 1730-1 [16425524.001]
  • [Cites] J Biol Chem. 2006 Jul 28;281(30):21546-57 [16728390.001]
  • [Cites] Oncology. 2006;70(3):203-11 [16809939.001]
  • [Cites] Lung Cancer. 2006 Oct;54(1):87-94 [16876904.001]
  • [Cites] Ai Zheng. 2006 Nov;25(11):1361-7 [17094902.001]
  • [Cites] Nat Rev Cancer. 2007 Mar;7(3):169-81 [17318210.001]
  • [Cites] Clin Cancer Res. 2007 May 1;13(9):2634-42 [17473194.001]
  • [Cites] Curr Opin Pulm Med. 2007 Jul;13(4):284-9 [17534174.001]
  • [Cites] J Biol Chem. 2007 Sep 14;282(37):27424-35 [17627939.001]
  • [Cites] Chest. 2007 Sep;132(3 Suppl):1S-19S [17873156.001]
  • [Cites] Nat Rev Cancer. 2007 Oct;7(10):778-90 [17882278.001]
  • [Cites] Biomed Pharmacother. 2007 Oct;61(9):515-9 [17913444.001]
  • [Cites] Annu Rev Pathol. 2006;1:331-48 [18039118.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5578-83 [18065730.001]
  • [Cites] Histol Histopathol. 2008 Jun;23(6):693-700 [18366007.001]
  • [Cites] Nature. 2008 Apr 3;452(7187):548-52 [18385728.001]
  • [Cites] Lancet Oncol. 2008 Jul;9(7):676-82 [18598932.001]
  • [Cites] Lung Cancer. 2009 Feb;63(2):164-8 [18599152.001]
  • [Cites] Diagn Cytopathol. 2009 Mar;37(3):178-83 [19170169.001]
  • [Cites] Cancer Res. 2009 Apr 1;69(7):2990-5 [19318550.001]
  • [Cites] Proc Am Thorac Soc. 2009 Apr 15;6(2):201-5 [19349489.001]
  • [Cites] Mod Pathol. 2009 Aug;22(8):1032-43 [19430419.001]
  • [Cites] Carcinogenesis. 2009 Nov;30(11):1903-9 [19736307.001]
  • [Cites] J Cell Mol Med. 2009 Aug;13(8B):1977-86 [19040416.001]
  • [Cites] Cancer. 2000 Dec 1;89(11 Suppl):2468-73 [11147629.001]
  • [Cites] Am J Clin Pathol. 2001 Dec;116(6):823-30 [11764070.001]
  • [Cites] EMBO J. 2002 Apr 2;21(7):1524-34 [11927537.001]
  • [Cites] Acta Odontol Latinoam. 2002;15(1-2):29-37 [15208940.001]
  • (PMID = 20447926.001).
  • [ISSN] 1538-7755
  • [Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
  • [ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P20 CA090578; United States / NCI NIH HHS / CA / R01 CA092824; United States / NCI NIH HHS / CA / CA070907-129004; United States / NCI NIH HHS / CA / P20 CA090578-05; United States / NCI NIH HHS / CA / CA092824; United States / NCI NIH HHS / CA / R01 CA074386; United States / NCI NIH HHS / CA / P50CA70907; United States / NCI NIH HHS / CA / R01 CA092824-07; United States / NCI NIH HHS / CA / CA074386; United States / NCI NIH HHS / CA / CA90578; United States / NCI NIH HHS / CA / P50 CA070907-129004; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / CA090578-05; United States / NCI NIH HHS / CA / P50 CA070907; United States / NCI NIH HHS / CA / CA092824-07; United States / NCI NIH HHS / CA / R01 CA074386-11
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / COL23A1 protein, human; 9007-34-5 / Collagen
  • [Other-IDs] NLM/ NIHMS186813; NLM/ PMC2880394
  •  go-up   go-down


18. Wosnitza M, Rübben A, Pallua N, Megahed M: [Eccrine adenocarcinoma in a patient with familial breast carcinoma]. Hautarzt; 2008 Nov;59(11):879-83
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Eccrine adenocarcinoma in a patient with familial breast carcinoma].
  • The histopathologic findings showed eccrine adenocarcinoma, a member of the heterogeneous group of sweat gland tumors which occur primarily in adults with a peak of 50-60 years of age.
  • Here further studies are needed to achieve a better survival rate for patients with metastatic disease.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Eccrine Glands / pathology. Sweat Gland Neoplasms / diagnosis. Sweat Gland Neoplasms / secondary

  • Hazardous Substances Data Bank. TAMOXIFEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Surg Oncol. 1989 Sep;42(1):69-72 [2770311.001]
  • [Cites] Cancer. 2003 May 1;97(9):2285-9 [12712485.001]
  • [Cites] Dermatol Surg. 2001 Apr;27(4):401-8 [11298716.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2004 Mar;113(3 Pt 1):242-4 [15053210.001]
  • [Cites] Conn Med. 2000 May;64(5):263-6 [10860232.001]
  • [Cites] J Surg Oncol. 1976;8(1):23-9 [1249938.001]
  • [Cites] World J Surg Oncol. 2003 Aug 1;1(1):13 [12921537.001]
  • [Cites] Hautarzt. 2008 Feb;59(2):151-60 [18214401.001]
  • [Cites] Adv Clin Path. 1999 Jul;3(3):63-8 [10655575.001]
  • [Cites] Mod Pathol. 2004 Jan;17(1):28-32 [14631375.001]
  • [Cites] Gan To Kagaku Ryoho. 1997 Jan;24(1):30-6 [9020942.001]
  • [Cites] Cancer. 1989 Jul 15;64(2):366-70 [2736482.001]
  • (PMID = 18931983.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Analgesics; 094ZI81Y45 / Tamoxifen
  •  go-up   go-down


19. Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Langmuir VK, Kroll S, Tidmarsh GT: A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J Cancer; 2009 Jun;45(9):1589-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.
  • PURPOSE: There are currently no approved therapies for patients with metastatic pancreatic adenocarcinoma previously treated with gemcitabine.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Agents, Alkylating / therapeutic use. Pancreatic Neoplasms / drug therapy. Phosphoramide Mustards / therapeutic use

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. GLUCOSE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19188061.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Phosphoramide Mustards; 0 / beta-D-glucosylisophosphoramide mustard; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; IY9XDZ35W2 / Glucose; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


20. Yu J, Seethala RR, Walls A, Cai G: Fine-needle aspiration of breast carcinoma metastatic to follicular variant of papillary thyroid carcinoma. Diagn Cytopathol; 2009 Sep;37(9):665-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine-needle aspiration of breast carcinoma metastatic to follicular variant of papillary thyroid carcinoma.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Breast Neoplasms / pathology. Carcinoma / secondary. Neoplasms, Second Primary / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19191290.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


21. Hong KP, Lee SJ, Hong GS, Yoon H, Shim BS: Prostate cancer metastasis to the stomach. Korean J Urol; 2010 Jun;51(6):431-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, we report a case of prostate cancer metastatic to the stomach.
  • A 66-year-old male was diagnosed with prostate adenocarcinoma.
  • A histopathologic examination and an esophagogastroduodenoscopic gastric biopsy revealed stomach-metastatic adenocarcinoma.
  • He was also noted as having cerebellar metastatic lesions, which were identified by using a brain magnetic resonance imaging (MRI) scan.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Med Res. 2010 Mar;8(1):18-21 [20305145.001]
  • [Cites] J Gastroenterol. 1997 Apr;32(2):236-40 [9085174.001]
  • [Cites] J Clin Gastroenterol. 1992 Apr;14(3):251-4 [1564301.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1596-600 [2311070.001]
  • [Cites] J Clin Gastroenterol. 2001 May-Jun;32(5):439-40 [11319319.001]
  • [Cites] Am J Dig Dis. 1975 Oct;20(10):903-13 [1190198.001]
  • [Cites] Urology. 2004 Apr;63(4):778-9 [15072903.001]
  • [Cites] Endoscopy. 2001 Jun;33(6):507-10 [11437044.001]
  • [Cites] Am J Gastroenterol. 1982 Jun;77(6):358-9 [7091119.001]
  • (PMID = 20577612.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2890062
  • [Keywords] NOTNLM ; Neoplasm metastasis / Prostatic neoplasms
  •  go-up   go-down


22. Bischiniotis TS, Lafaras CT, Platogiannis DN, Moldovan L, Barbetakis NG, Katseas GP: Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade. Hellenic J Cardiol; 2005 Sep-Oct;46(5):324-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intrapericardial cisplatin administration after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade.
  • INTRODUCTION: Patients with lung adenocarcinoma often suffer from metastatic pericardial effusion that may eventually cause cardiac tamponade.
  • We evaluated the safety and effectiveness of the intrapericardial infusion of cisplatin, a substance with antineoplastic and sclerosing properties, after pericardiocentesis in patients with lung adenocarcinoma and malignant cardiac tamponade.
  • METHODS: Twenty-five patients (19 males and 6 females, median age 55 years) with lung adenocarcinoma confirmed by cytological examination and cardiac tamponade were studied.
  • CONCLUSIONS: Intrapericardial administration of cisplatin is safe and effective in preventing the reaccumulation of malignant pericardial effusion in the majority of patients with lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / surgery. Cisplatin / administration & dosage. Lung Neoplasms / surgery. Pericardiocentesis. Pleural Effusion, Malignant / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16295940.001).
  • [ISSN] 1109-9666
  • [Journal-full-title] Hellenic journal of cardiology : HJC = Hellēnikē kardiologikē epitheōrēsē
  • [ISO-abbreviation] Hellenic J Cardiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


23. Sanada Y, Yoshida K, Konishi K, Oeda M, Ohara M, Tsutani Y: Expression of gastric mucin MUC5AC and gastric transcription factor SOX2 in ampulla of vater adenocarcinoma: comparison between expression patterns and histologic subtypes. Oncol Rep; 2006 May;15(5):1157-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of gastric mucin MUC5AC and gastric transcription factor SOX2 in ampulla of vater adenocarcinoma: comparison between expression patterns and histologic subtypes.
  • The purpose of this study was to examine the expression pattern of MUC5AC and SOX2 in ampulla of vater adenocarcinoma and evaluate the association between expression of these gastric epithelial markers and the histologic phenotype of ampulla of vater carcinoma.
  • Six surgically resected samples of ampulla of vater adenocarcinoma, including four intestinal type carcinomas and two pancreatobiliary type carcinomas, were studied.
  • However, in the centre of the tumour and in other invasive lesions, including vascular invasive lesions and metastatic lymph nodes, neither MUC5AC nor SOX2 was expressed.
  • [MeSH-major] Adenocarcinoma / metabolism. Ampulla of Vater / metabolism. Common Bile Duct Neoplasms / metabolism. HMGB Proteins / metabolism. Mucins / metabolism. Pancreatic Neoplasms / metabolism. Stomach Neoplasms / metabolism. Transcription Factors / metabolism

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16596179.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / HMGB Proteins; 0 / MUC5AC protein, human; 0 / Mucin 5AC; 0 / Mucins; 0 / SOX2 protein, human; 0 / SOXB1 Transcription Factors; 0 / Transcription Factors
  •  go-up   go-down


24. Zheng LD, Yang XP, Pan HX, Nie X, He J, Lv Q, Tong QS: Gastric carcinoma with osteoclast-like giant cells: a case report and review of the literature. J Zhejiang Univ Sci B; 2009 Mar;10(3):237-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The biopsy and pathological findings indicated a gastric adenocarcinoma with OGCs, which were present in both the tumor and the metastatic lymph nodes.
  • In situ hybridization for Epstein-Barr virus showed no nuclear positivity in either adenocarcinoma or OGCs.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1991 Sep;139(3):469-74 [1653517.001]
  • [Cites] Diagn Cytopathol. 2007 Sep;35(9):555-9 [17703447.001]
  • [Cites] Am J Clin Pathol. 1995 Apr;103(4):453-9 [7726143.001]
  • [Cites] Ultrastruct Pathol. 1996 Jan-Feb;20(1):89-99 [8789215.001]
  • [Cites] Cancer. 1998 Apr 1;82(7):1279-87 [9529019.001]
  • [Cites] Ann Diagn Pathol. 1998 Aug;2(4):229-40 [9845743.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1678-81 [10364044.001]
  • [Cites] Am J Dermatopathol. 2005 Apr;27(2):126-9 [15798437.001]
  • [Cites] Histopathology. 2005 May;46(5):590-2 [15842645.001]
  • [Cites] Histopathology. 2005 Sep;47(3):331-3 [16115241.001]
  • [Cites] J Gastroenterol. 2006 Jan;41(1):83-7 [16501862.001]
  • [Cites] Hum Pathol. 2006 Mar;37(3):369-72 [16613333.001]
  • [Cites] Pancreas. 2006 Oct;33(3):304-10 [17003654.001]
  • [Cites] Diagn Cytopathol. 2007 Feb;35(2):111-2 [17230568.001]
  • [Cites] Pancreas. 1992;7(5):611-5 [1513808.001]
  • (PMID = 19283880.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Number-of-references] 16
  • [Other-IDs] NLM/ PMC2650035
  •  go-up   go-down


25. Kelly T, Suva LJ, Huang Y, Macleod V, Miao HQ, Walker RC, Sanderson RD: Expression of heparanase by primary breast tumors promotes bone resorption in the absence of detectable bone metastases. Cancer Res; 2005 Jul 1;65(13):5778-84
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These factors exert a distal effect resulting in resorption of bone and the accompanying enrichment of the bone microenvironment with growth-promoting factors that may nurture the growth of metastatic tumor cells.
  • [MeSH-major] Adenocarcinoma / enzymology. Bone Resorption / enzymology. Breast Neoplasms / enzymology. Glucuronidase / biosynthesis

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994953.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA10354; United States / NCI NIH HHS / CA / CA68494; United States / NIDDK NIH HHS / DK / DK054044
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.- / heparanase; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


26. Min BS, Kim JS, Kim NK, Lim JS, Lee KY, Cho CH, Sohn SK: Extended lymph node dissection for rectal cancer with radiologically diagnosed extramesenteric lymph node metastasis. Ann Surg Oncol; 2009 Dec;16(12):3271-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pathologic examinations revealed metastatic para-aortic lymph nodes in 43 patients (PA) and metastatic lateral pelvic nodes in 36 patients (LP), while in 21 patients, metastasis was found in both (LP + PA).
  • [MeSH-major] Adenocarcinoma / surgery. Adenocarcinoma, Mucinous / surgery. Lymph Node Excision. Rectal Neoplasms / surgery

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19763693.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


27. Kim YJ, Im SA, Kim HG, Oh SY, Lee KW, Choi IS, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Kim SW, Heo DS, Yoon YB, Bang YJ: A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer. Ann Oncol; 2008 Jan;19(1):99-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
  • We carried out this study to evaluate the efficacy and toxicity of combination chemotherapy with S-1 and cisplatin in metastatic or relapsed BTC.
  • RESULTS: Fifty-one BTC patients (metastatic:relapsed = 37:14, Gall-bladder:intrahepatic bile ducts:extrahepatic bile ducts = 16:25:10) were enrolled from January 2005 to December 2006.

  • Genetic Alliance. consumer health - Biliary Tract Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17846018.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin; UA8SE1325T / gimeracil
  •  go-up   go-down


28. Nair KS, Naidoo R, Chetty R: Expression of cell adhesion molecules in oesophageal carcinoma and its prognostic value. J Clin Pathol; 2005 Apr;58(4):343-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It has been established that the initial step in the metastatic cascade is the detachment of tumour cells from the primary tumour via dysregulation of normal cell-cell and cell-matrix interactions.
  • This review provides a brief description of five families of CAMs (cadherins, integrins, CD44, immunoglobulin superfamily, and selectins) and highlights their altered expression in relation both to prognosis and tumour behaviour in squamous cell carcinoma and adenocarcinoma of the oesophagus.
  • [MeSH-minor] Adenocarcinoma / chemistry. Antigens, CD44 / analysis. Cadherins / analysis. Carcinoma, Squamous Cell / chemistry. Humans. Integrins / analysis. Neoplasm Metastasis. Prognosis. Selectins / analysis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1998 Jan;32(1):7-14 [9522210.001]
  • [Cites] J Cell Physiol. 1998 Sep;176(3):482-94 [9699501.001]
  • [Cites] Cancer. 1998 Sep 1;83(5):858-66 [9731887.001]
  • [Cites] Chest. 1999 Dec;116(6 Suppl):463S-465S [10619509.001]
  • [Cites] Mol Pathol. 1999 Aug;52(4):189-96 [10694938.001]
  • [Cites] Mol Pathol. 1999 Aug;52(4):208-13 [10694941.001]
  • [Cites] Int J Oncol. 2000 Apr;16(4):677-82 [10717234.001]
  • [Cites] Int J Oncol. 2000 Apr;16(4):725-9 [10717240.001]
  • [Cites] Genes Dev. 2000 Aug 1;14(15):1837-51 [10921899.001]
  • [Cites] Br J Surg. 2000 Aug;87(8):992-1005 [10931041.001]
  • [Cites] J Cell Biol. 2000 Aug 7;150(3):567-80 [10931868.001]
  • [Cites] Int J Oncol. 2000 Oct;17(4):701-5 [10995880.001]
  • [Cites] Breast Cancer. 2000 Jan;7(1):19-26 [11029766.001]
  • [Cites] Cell Biol Int. 2001;25(1):61-9 [11237409.001]
  • [Cites] Clin Chem. 2001 Apr;47(4):624-30 [11274010.001]
  • [Cites] Oncol Rep. 2001 Sep-Oct;8(5):981-5 [11496302.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3519-25 [11705871.001]
  • [Cites] J Clin Invest. 2002 Apr;109(8):999-1006 [11956235.001]
  • [Cites] J Cell Biol. 1991 Sep;114(5):1059-68 [1874786.001]
  • [Cites] Annu Rev Biochem. 1991;60:155-90 [1883195.001]
  • [Cites] J Clin Lab Anal. 1991;5(5):344-66 [1941355.001]
  • [Cites] J Cell Biol. 1991 Dec;115(6):1751-61 [1757472.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 15;89(6):2292-6 [1372439.001]
  • [Cites] Cell. 1992 Apr 3;69(1):11-25 [1555235.001]
  • [Cites] Cell. 1992 Apr 17;69(2):225-36 [1568244.001]
  • [Cites] J Pathol. 1992 May;167(1):77-82 [1625062.001]
  • [Cites] J Pathol. 1992 Jun;167(2):187-91 [1378891.001]
  • [Cites] Cell. 1992 Jul 24;70(2):293-301 [1638632.001]
  • [Cites] Lancet. 1992 Oct 31;340(8827):1053-8 [1357452.001]
  • [Cites] Br J Cancer. 1992 Oct;66(4):629-34 [1384639.001]
  • [Cites] J Cell Biol. 1993 Feb;120(3):577-85 [8381117.001]
  • [Cites] Lancet. 1993 Mar 20;341(8847):725-6 [8095628.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):981-6 [7682766.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):987-93 [7682767.001]
  • [Cites] J Surg Oncol. 1993 Jun;53(2):78-83 [8501910.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):122-4 [7686390.001]
  • [Cites] J Cell Biol. 1993 Jul;122(2):431-42 [8320265.001]
  • [Cites] Br J Cancer. 1993 Aug;68(2):428-32 [8347502.001]
  • [Cites] Cancer Res. 1993 Sep 15;53(18):4197-203 [7689929.001]
  • [Cites] J Biol Chem. 1993 Oct 25;268(30):22883-94 [8226797.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):630-1 [7505052.001]
  • [Cites] Nature. 1993 Dec 16;366(6456):695-8 [7505053.001]
  • [Cites] Cancer Res. 1994 Jan 1;54(1):291-6 [8261454.001]
  • [Cites] Cell. 1994 Jan 28;76(2):301-14 [7507411.001]
  • [Cites] J Cell Biol. 1994 Feb;124(4):589-600 [8106556.001]
  • [Cites] Cancer. 1994 Mar 1;73(5):1324-31 [7906606.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3007-10 [8187090.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1327-40 [8207061.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):391-401 [7518464.001]
  • [Cites] Semin Oncol. 1994 Aug;21(4):425-30 [8042040.001]
  • [Cites] J Cell Biol. 1994 Aug;126(4):1099-109 [7519619.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Aug 16;91(17):8263-7 [8058792.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2068-101 [7522621.001]
  • [Cites] J Biol Chem. 1994 Oct 28;269(43):26602-5 [7929388.001]
  • [Cites] J Cell Physiol. 1997 Oct;173(1):54-63 [9326449.001]
  • [Cites] J Pathol. 1997 Jul;182(3):331-8 [9349237.001]
  • [Cites] Blood. 1997 Nov 15;90(10):4039-45 [9354673.001]
  • [Cites] Int J Cancer. 1997 Dec 19;74(6):582-7 [9421352.001]
  • [Cites] Am J Pathol. 1998 Jan;152(1):135-44 [9422531.001]
  • [Cites] J Cell Biol. 1997 Jun 16;137(6):1421-31 [9182672.001]
  • [Cites] Cancer. 1998 Sep 15;83(6):1074-80 [9740070.001]
  • [Cites] Clin Cancer Res. 1996 Jul;2(7):1097-102 [9816273.001]
  • [Cites] Cell. 1996 Oct 18;87(2):175-85 [8861902.001]
  • [Cites] Science. 1996 Nov 15;274(5290):1123-33 [8895455.001]
  • [Cites] Dev Biol. 1996 Dec 15;180(2):402-12 [8954713.001]
  • [Cites] Br J Surg. 1996 Nov;83(11):1608-14 [9014688.001]
  • [Cites] Clin Cancer Res. 1998 Feb;4(2):407-10 [9516929.001]
  • [Cites] J Clin Invest. 1997 Jul 1;100(1):1-5 [9202049.001]
  • [Cites] EMBO J. 1997 Jul 1;16(13):3797-804 [9233789.001]
  • [Cites] J Pathol. 1998 Sep;186(1):1-2 [9875132.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jan 5;96(1):139-44 [9874785.001]
  • [Cites] J Cell Biol. 1999 Mar 22;144(6):1311-22 [10087272.001]
  • [Cites] Semin Cancer Biol. 1999 Apr;9(2):67-81 [10202129.001]
  • [Cites] Am J Med. 1999 Apr;106(4):467-76 [10225251.001]
  • [Cites] Am J Pathol. 1999 Apr;154(4):965-73 [10233832.001]
  • [Cites] Hepatogastroenterology. 1999 Mar-Apr;46(26):938-43 [10370643.001]
  • [Cites] Cell Growth Differ. 1999 Jun;10(6):369-76 [10392898.001]
  • [Cites] J Biol Chem. 1999 Jul 23;274(30):21409-15 [10409703.001]
  • [Cites] Curr Opin Cell Biol. 1999 Oct;11(5):591-6 [10508646.001]
  • [Cites] J Exp Med. 1965 Mar 1;121:439-62 [14270243.001]
  • [Cites] Anticancer Res. 2002 May-Jun;22(3):1849-57 [12168881.001]
  • [Cites] J Cell Biol. 2002 Sep 2;158(5):953-65 [12213839.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):225-32 [12532436.001]
  • [Cites] Surgery. 2003 Feb;133(2):162-9 [12605177.001]
  • [Cites] Anticancer Res. 2003 Jan-Feb;23(1A):161-5 [12680208.001]
  • [Cites] J Neurosurg. 2003 May;98(5):1084-93 [12744370.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23(6a):4435-42 [14666731.001]
  • [Cites] Cancer Res. 1986 Jan;46(1):1-7 [2998604.001]
  • [Cites] J Cell Biol. 1987 May;104(5):1361-74 [3553211.001]
  • [Cites] J Exp Med. 1987 Oct 1;166(4):1125-31 [3655655.001]
  • [Cites] J Pathol. 1988 Jul;155(3):207-12 [3411381.001]
  • [Cites] Development. 1988 Apr;102(4):639-55 [3048970.001]
  • [Cites] Biochim Biophys Acta. 1988 Nov 15;948(2):175-224 [3052592.001]
  • [Cites] Cell. 1989 Apr 21;57(2):327-34 [2702691.001]
  • [Cites] Science. 1989 Dec 8;246(4935):1303-6 [2588007.001]
  • [Cites] Science. 1990 Jan 5;247(4938):49-56 [2294591.001]
  • [Cites] Cancer Res. 1990 Feb 15;50(4):1271-8 [1967552.001]
  • [Cites] J Cell Biol. 1990 Feb;110(2):349-57 [2153683.001]
  • [Cites] Cell. 1990 Feb 23;60(4):577-84 [1689216.001]
  • [Cites] Cancer Metastasis Rev. 1989 Dec;8(3):263-80 [2697474.001]
  • [Cites] Science. 1990 Mar 9;247(4947):1219-22 [1690453.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Jun;87(11):4246-50 [2349235.001]
  • [Cites] Cell. 1990 Jun 29;61(7):1303-13 [1694723.001]
  • [Cites] Nature. 1990 Aug 2;346(6283):425-34 [1974032.001]
  • [Cites] FASEB J. 1990 Aug;4(11):2868-80 [2199285.001]
  • [Cites] Lab Invest. 1990 Dec;63(6):780-91 [1979361.001]
  • [Cites] Cell. 1991 May 31;65(5):849-57 [1904011.001]
  • [Cites] Cell. 1991 Jul 12;66(1):107-19 [2070412.001]
  • [Cites] Cancer Res. 1994 Dec 1;54(23):6282-7 [7954478.001]
  • [Cites] Gut. 1994 Oct;35(10):1343-7 [7959182.001]
  • [Cites] J Cell Biol. 1994 Dec;127(6 Pt 2):2061-9 [7806582.001]
  • [Cites] Curr Opin Cell Biol. 1994 Oct;6(5):663-73 [7530461.001]
  • [Cites] Cell. 1995 Feb 10;80(3):413-22 [7532110.001]
  • [Cites] Nature. 1995 Mar 23;374(6520):327-37 [7885471.001]
  • [Cites] J Biol Chem. 1995 Mar 10;270(10):5549-55 [7890674.001]
  • [Cites] J Cell Biol. 1995 Jul;130(1):67-77 [7790378.001]
  • [Cites] FASEB J. 1995 Jul;9(10):866-73 [7542213.001]
  • [Cites] J Cell Biol. 1995 Jul;130(2):451-60 [7542249.001]
  • [Cites] Mol Biol Cell. 1995 Apr;6(4):419-31 [7542940.001]
  • [Cites] J Clin Pathol. 1995 Jun;48(6):539-44 [7665697.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Sep 12;92(19):8813-7 [7568023.001]
  • [Cites] J Pathol. 1995 Sep;177(1):11-20 [7472774.001]
  • [Cites] Am J Pathol. 1995 Dec;147(6):1823-39 [7495306.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):634-40 [8573337.001]
  • [Cites] Science. 1996 Apr 5;272(5258):60-6 [8600538.001]
  • [Cites] Cancer Lett. 1996 Apr 19;102(1-2):183-91 [8603368.001]
  • [Cites] Br J Surg. 1996 May;83(5):588-601 [8689199.001]
  • [Cites] Oncology. 1997 Mar-Apr;54(2):158-65 [9075789.001]
  • [Cites] Trends Genet. 1997 Apr;13(4):157-62 [9097727.001]
  • [Cites] Proc Soc Exp Biol Med. 1999 Nov;222(2):124-38 [10564536.001]
  • [Cites] Gut. 2000 Jan;46(1):14-9 [10601048.001]
  • (PMID = 15790695.001).
  • [ISSN] 0021-9746
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Cadherins; 0 / Cell Adhesion Molecules; 0 / Integrins; 0 / Selectins
  • [Number-of-references] 132
  • [Other-IDs] NLM/ PMC1770622
  •  go-up   go-down


29. Sato Y, Ishii H, Terada T, Amaya S, Koizumi H, Fujisawa K, Munemoto Y, Mitsui T, Iida Y, Miura S: [A case of AFP-producing gastric cancer with hepatic metastases that accompanied early gastric cancer treated effectively by chemotherapy]. Gan To Kagaku Ryoho; 2010 Oct;37(10):1957-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abdominal CT showed multiple metastatic lesions in the liver.
  • After 5 courses of postoperative administration of S-1, hepatic metastatic lesions disappeared on imaging.
  • Since the concurrence of AFP-producing gastric cancer and tubular adenocarcinoma is rare, and hepatic metastatic lesions disappeared, the case under study is considered to be of interest.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20976991.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Drug Combinations; 0 / alpha-Fetoproteins; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


30. André T, Wislez M, Goncalves A, de La Motte Rouge T, Blay JY, Massard C, Bay JO, comité de rédaction du Bulletin du Cancer: [Following communications made at American Society of Clinical Oncology 2010, what will change our practice? The point of view of the editorial board of Bulletin du Cancer]. Bull Cancer; 2010 Dec;97(12):1551-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Suite aux communications faites au congrès de l'American Society of Clinical Oncology 2010, qu'est ce qui va changer nos pratiques ? Le point de vue du comité de rédaction du Bulletin du cancer.
  • The identification of the gene of fusion EML4-ALK in lung adenocarcinoma, and its inhibition by the crizotinib, constitute a considerable progress for 5% of patients with this disease.
  • In metastatic adenocarcinoma of the pancreas, there is finally an alternative to gemcitabine with the Folfirinox regimen, with an improvement of overall survival.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21220230.001).
  • [ISSN] 1769-6917
  • [Journal-full-title] Bulletin du cancer
  • [ISO-abbreviation] Bull Cancer
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


31. Sanchez LD, Chelliah T, Meisher I, Niranjan S: Rare case of breast tumor secondary to rectal adenocarcinoma. South Med J; 2008 Oct;101(10):1062-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rare case of breast tumor secondary to rectal adenocarcinoma.
  • Metastatic cancer to the breast is very rare.
  • [MeSH-major] Adenocarcinoma / secondary. Breast Neoplasms / secondary. Rectal Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18791504.001).
  • [ISSN] 1541-8243
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Parlea L, Fahim L, Munoz D, Hanna A, Anderson J, Cusimano M, Kovacs K, Gardiner G: Follicular carcinoma of the thyroid with aggressive metastatic behavior in a pregnant woman: report of a case and review of the literature. Hormones (Athens); 2006 Oct-Dec;5(4):295-302
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Follicular carcinoma of the thyroid with aggressive metastatic behavior in a pregnant woman: report of a case and review of the literature.
  • We suggest that architectural differentiation of the tumor and cell proliferation rate are not reliable markers of metastatic behavior in this particular thyroid neoplasm.
  • Microvascular density and down-regulation of E-cadherin expression in the tumor should be included among histologic hallmarks of metastatic potential. the role of pregnancy in the aggressive behavior of this tumor is discussed along with a literature review.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Bone Neoplasms / secondary. Lung Neoplasms / secondary. Pregnancy Complications, Neoplastic / pathology. Thyroid Neoplasms / pathology


33. Malle D, Valeri RM, Photiou C, Kaplanis K, Andreadis C, Tsavdaridis D, Destouni C: Significance of immunocytochemical expression of E-cadherin, N-cadherin and CD44 in serous effusions using liquid-based cytology. Acta Cytol; 2005 Jan-Feb;49(1):11-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the diagnostic utility of E-cadherin (E-cad), N-cadherin (N-cad) and CD44 to discriminate adenocarcinoma cells from benign and malignant mesothelial cells in body cavity fluids and to clarify the origin of cancer cells.
  • STUDY DESIGN: A total of 120 ThinPrep (Cytyc Corp., Boxborough, Massachusetts, U.S.A.) cytologic specimens of serous effusions, which included 22 cases of reactive mesothelium, 6 cases of malignant mesothelioma and 92 cases of metastatic adenocarcinoma from various sites, were immunostained for E-cad, N-cad and CD44.
  • RESULTS: Eighty-three of 92 metastatic adenocarcinomas (90.21%) expressed E-cad, while 1 of 6 malignant mesotheliomas and 1 of 22 cases of reactive mesothelium were positive for E-cad.
  • All 6 cases of mesothelioma expressed N-cad, whereas most cases of metastatic adenocarcinomas were negative.
  • CD44 immunoreactivity was seen in 18 of 22 (81.81%) benign effusions and in 21 of 92 (22.82%) metastatic adenocarcinomas.
  • CONCLUSION: The combination of E-cad, N-cad and CD44 appears to be a useful panel for distinguishing metastatic adenocarcinoma, mesothelioma and reactive mesothelium and also for clarifying the exact histogenetic origin of cancer cells.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Breast Neoplasms / diagnosis. Breast Neoplasms / metabolism. Breast Neoplasms / pathology. Cytodiagnosis. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Lung Neoplasms / diagnosis. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Mesothelioma / diagnosis. Mesothelioma / metabolism. Mesothelioma / pathology. Retrospective Studies


34. MacDougall CA, Vargas M, Soares CR, Holzer RG, Ide AE, Jorcyk CL: Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c. Prostate; 2005 Jul 1;64(2):139-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Involvement of HGF/SF-Met signaling in prostate adenocarcinoma cells: evidence for alternative mechanisms leading to a metastatic phenotype in Pr-14c.
  • BACKGROUND: Hepatocyte growth factor/scatter factor (HGF/SF) facilitates intercellular communication between the epithelial carcinoma and its surrounding stromal tissue during metastatic invasion through interaction with its proto-oncogenic receptor, Met, found on carcinoma cells.
  • This study utilizes the C31/Tag transgenic mouse prostate cancer cell line model in an attempt to characterize the interaction between HGF/SF and Met on the metastatic potential of prostate cancer.
  • METHODS: Exogenous HGF was supplied to the prostate adenocarcinoma cell line (Pr-14) and metastatic cell line (Pr-14c) to evaluate mitogenicity by proliferation assays, morphological characteristics on an extracellular matrix substrate, and motogenic properties using the scatter assay, invasion chambers, and zymogram studies to analyze secretory enzymes produced by the cell lines.
  • Pr-14 cells have an increased growth rate following HGF/SF treatment, whereas the metastatic Pr-14c cells show little change.
  • Motility studies of the metastatic cells following HGF/SF treatment reveal a potentially faulty signaling pathway downstream of Met activation in the metastatic prostate cells.
  • CONCLUSIONS: Our studies suggest that proliferation, invasion, and cell morphological characteristics may be induced independently from the HGF/SF-Met pathway in C31/Tag metastatic prostate cancer cells.
  • [MeSH-major] Adenocarcinoma / genetics. Hepatocyte Growth Factor / genetics. Prostatic Neoplasms / genetics. Proto-Oncogene Proteins c-met / genetics

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 15678502.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


35. Moore A, Lau E, Yang C, Mackool B, Kuter DJ: Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma. Am J Clin Oncol; 2007 Jun;30(3):329-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dalteparin-induced skin necrosis in a patient with metastatic lung adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / complications. Anticoagulants / adverse effects. Dalteparin / adverse effects. Lung Neoplasms / complications. Skin Diseases / chemically induced

  • MedlinePlus Health Information. consumer health - Blood Thinners.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551316.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anticoagulants; S79O08V79F / Dalteparin
  •  go-up   go-down


36. Centeno BA: Pathology of liver metastases. Cancer Control; 2006 Jan;13(1):13-26
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The liver is the most frequent site of metastatic disease, and metastatic disease to the liver is far more common than primary liver carcinoma in the United States.
  • Morphologic and immunoperoxidase studies, which are the standard for pathologic practice, accurately classify most tumors.
  • Many malignancies have distinct morphologic and immunohistochemical patterns and can be correctly subclassified.
  • Adenocarcinoma of unknown primary remains enigmatic since current immunohistochemical markers for this differential diagnosis lack specificity.
  • CONCLUSIONS: Most metastatic malignancies in the liver may be correctly diagnosed using standard morphology and immunohistochemical techniques.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16508622.001).
  • [ISSN] 1073-2748
  • [Journal-full-title] Cancer control : journal of the Moffitt Cancer Center
  • [ISO-abbreviation] Cancer Control
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 101
  •  go-up   go-down


37. Pittman KB, Olver IN, Koczwara B, Kotasek D, Patterson WK, Keefe DM, Karapetis CS, Parnis FX, Moldovan S, Yeend SJ, Price TJ, Adelaide Cancer Trials and Education Collaborative (ACTEC): Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. Br J Cancer; 2006 Nov 20;95(10):1309-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients with histologically confirmed metastatic carcinoma in which the primary site of cancer was not evident after prospectively designated investigation and who had ECOG performance status 0-2 were treated with G 1000 mg m(-2) intravenously (i.v.) days 1 and 8, and C AUC 5 i.v. on day 8 every 3 weeks to a maximum of nine cycles.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Australia. Carboplatin / administration & dosage. Carcinoma, Large Cell / drug therapy. Carcinoma, Large Cell / secondary. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Male. Maximum Tolerated Dose. Middle Aged. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • Hazardous Substances Data Bank. CARBOPLATIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1997 May;15(5):2056-66 [9164218.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Jpn J Clin Oncol. 2004 Nov;34(11):681-5 [15613558.001]
  • [Cites] Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:36-41 [15839957.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8380-8 [16293868.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3101-7 [10963638.001]
  • [Cites] Ann Oncol. 2000 Jul;11(7):883-4 [10997819.001]
  • [Cites] J Clin Oncol. 2002 Mar 15;20(6):1651-6 [11896116.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4679-83 [12488413.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3479-82 [12972523.001]
  • [Cites] Urology. 2004 Sep;64(3):479-84 [15351574.001]
  • [Cites] Biometrics. 1982 Mar;38(1):143-51 [7082756.001]
  • [Cites] J Clin Oncol. 1989 Nov;7(11):1748-56 [2681557.001]
  • [Cites] Semin Oncol. 1993 Jun;20(3):261-7 [7684858.001]
  • [Cites] Semin Oncol. 1998 Aug;25(4 Suppl 9):51-4 [9728585.001]
  • (PMID = 17088914.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; BG3F62OND5 / Carboplatin
  • [Other-IDs] NLM/ PMC2360587
  •  go-up   go-down


38. Verigos K, Stripp DC, Mick R, Zhu TC, Whittington R, Smith D, Dimofte A, Finlay J, Busch TM, Tochner ZA, Malkowicz S, Glatstein E, Hahn SM: Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer. J Environ Pathol Toxicol Oncol; 2006;25(1-2):373-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifteen men with biopsy-proven locally recurrent prostate cancer and no evidence of distant metastatic disease have been enrolled and 14 have been treated.
  • [MeSH-major] Adenocarcinoma / drug therapy. Metalloporphyrins / therapeutic use. Photochemotherapy / adverse effects. Photosensitizing Agents / therapeutic use. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16566729.001).
  • [ISSN] 0731-8898
  • [Journal-full-title] Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer
  • [ISO-abbreviation] J. Environ. Pathol. Toxicol. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-88064
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Metalloporphyrins; 0 / Photosensitizing Agents; 0A85BJ22L6 / motexafin lutetium
  •  go-up   go-down


39. Koopman M, Kortman GA, Mekenkamp L, Ligtenberg MJ, Hoogerbrugge N, Antonini NF, Punt CJ, van Krieken JH: Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer; 2009 Jan 27;100(2):266-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This supports the hypothesis that dMMR tumours have a reduced metastatic potential, as is observed in dMMR patients with early stage disease.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma, Mucinous / genetics. Carcinoma, Adenosquamous / genetics. Colorectal Neoplasms / genetics. DNA Mismatch Repair / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastroenterology. 1999 Jul;117(1):123-31 [10381918.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1637-41 [10362787.001]
  • [Cites] Gut. 2005 Feb;54(2):264-7 [15647192.001]
  • [Cites] J Clin Oncol. 2005 Jan 20;23(3):609-18 [15659508.001]
  • [Cites] Clin Cancer Res. 2005 Jun 1;11(11):4234-40 [15930362.001]
  • [Cites] Clin Cancer Res. 2005 Dec 1;11(23):8332-40 [16322293.001]
  • [Cites] Ann Thorac Surg. 2006 Jun;81(6):2008-13 [16731121.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • [Cites] Histopathology. 2007 Jan;50(1):113-30 [17204026.001]
  • [Cites] Eur J Cancer. 2007 Jun;43(9):1348-60 [17512720.001]
  • [Cites] Clin Cancer Res. 2007 Jun 1;13(11):3221-8 [17545526.001]
  • [Cites] Br J Cancer. 2007 May 21;96(10):1605-12 [17453009.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3831-9 [17606714.001]
  • [Cites] Lancet. 2007 Jul 14;370(9582):135-42 [17630036.001]
  • [Cites] J Clin Oncol. 2008 Jun 1;26(16):2690-8 [18509181.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1246-51 [18677806.001]
  • [Cites] Int J Colorectal Dis. 2008 Nov;23(11):1033-9 [18594845.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Nov;17(11):3208-15 [18990764.001]
  • [Cites] Cancer. 1990 Nov 15;66(10):2162-7 [2171747.001]
  • [Cites] N Engl J Med. 2000 Jan 13;342(2):69-77 [10631274.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Gut. 2001 Jun;48(6):821-9 [11358903.001]
  • [Cites] Am J Hum Genet. 2001 Oct;69(4):780-90 [11524701.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Sep;10(9):917-23 [11535541.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1043-8 [11844828.001]
  • [Cites] Gastroenterology. 2002 May;122(5):1376-87 [11984524.001]
  • [Cites] Cancer Chemother Pharmacol. 2002 Jun;49(6):445-52 [12107548.001]
  • [Cites] Int J Cancer. 2002 Sep 1;101(1):23-31 [12209584.001]
  • [Cites] Int J Cancer. 2002 Oct 20;101(6):519-25 [12237891.001]
  • [Cites] Clin Colorectal Cancer. 2001 Aug;1(2):104-9 [12445368.001]
  • [Cites] Am J Pathol. 2003 Feb;162(2):469-77 [12547705.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1174-9 [12637487.001]
  • [Cites] Int J Cancer. 2003 Aug 10;106(1):66-73 [12794758.001]
  • [Cites] N Engl J Med. 2003 Jul 17;349(3):247-57 [12867608.001]
  • [Cites] J Clin Oncol. 2003 Oct 15;21(20):3729-36 [14551292.001]
  • [Cites] Gastroenterology. 2004 Feb;126(2):394-401 [14762775.001]
  • [Cites] Fam Cancer. 2004;3(2):101-7 [15340260.001]
  • [Cites] Ann Oncol. 2004 Oct;15(10):1453-9 [15367403.001]
  • [Cites] Int J Colorectal Dis. 2004 Nov;19(6):533-7 [15175889.001]
  • [Cites] Gastroenterology. 1987 Nov;93(5):1021-5 [2820826.001]
  • [Cites] Science. 1993 May 7;260(5109):812-6 [8484121.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):558-61 [8505985.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5849-52 [8261392.001]
  • [Cites] Gastroenterology. 1996 Mar;110(3):682-7 [8608876.001]
  • [Cites] Cancer Res. 1996 Nov 1;56(21):4881-6 [8895738.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):808-11 [9041175.001]
  • [Cites] Diagn Mol Pathol. 1997 Apr;6(2):78-84 [9098645.001]
  • [Cites] J Natl Cancer Inst. 1997 Dec 3;89(23):1758-62 [9392616.001]
  • [Cites] Cancer Res. 1998 Aug 1;58(15):3455-60 [9699680.001]
  • [Cites] Cancer Res. 1998 Nov 15;58(22):5248-57 [9823339.001]
  • [Cites] Ann Surg Oncol. 2004 Nov;11(11):977-82 [15525826.001]
  • (PMID = 19165197.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / MLH1 protein, human; 0 / Nuclear Proteins; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0H43101T0J / irinotecan; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 3.6.1.3 / MutL Protein Homolog 1; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2634718
  •  go-up   go-down


40. Oshikiri T, Morita T, Fujita M, Miyasaka Y, Senmaru N, Yamada H, Kaji N, Kondo S: Resection of lung metastasis from gallbladder carcinoma: immunohistochemistry of RCAS1 and CD8+T cells in primary and metastatic tumors. Cancer Lett; 2006 Jun 8;237(1):115-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resection of lung metastasis from gallbladder carcinoma: immunohistochemistry of RCAS1 and CD8+T cells in primary and metastatic tumors.
  • However, infiltration of CD8+T cells was only seen in the lung metastatic tumor.
  • [MeSH-major] Adenocarcinoma, Papillary / metabolism. Antigens, Neoplasm / metabolism. CD8-Positive T-Lymphocytes / pathology. Gallbladder Neoplasms / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Lymphocytes, Tumor-Infiltrating / pathology

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16039043.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / EBAG9 protein, human
  •  go-up   go-down


41. Parnaby CN, Chong PS, Chisholm L, Farrow J, Connell JM, O'Dwyer PJ: The role of laparoscopic adrenalectomy for adrenal tumours of 6 cm or greater. Surg Endosc; 2008 Mar;22(3):617-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three with metastatic adrenal carcinoma and two with severe cardiorespiratory disease were deemed unsuitable for operation.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adrenal Gland Neoplasms / pathology. Adrenal Gland Neoplasms / surgery. Adrenalectomy / methods. Laparoscopy / methods

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2002 Aug;26(8):1043-7 [12045859.001]
  • [Cites] Surg Endosc. 2003 Dec;17 (12 ):1905-9 [14577024.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):749-64 [9735132.001]
  • [Cites] Am J Surg Pathol. 2002 Dec;26(12):1612-9 [12459628.001]
  • [Cites] Surgery. 1997 Dec;122(6):1132-6 [9426429.001]
  • [Cites] Br J Surg. 1999 May;86(5):656-60 [10361189.001]
  • [Cites] Eur J Surg Oncol. 2004 May;30(4):444-9 [15063900.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):238-46; discussion 246-7 [9339930.001]
  • [Cites] Surg Endosc. 2002 Feb;16(2):252-7 [11967673.001]
  • [Cites] G Chir. 2001 Mar;22(3):101-6 [11284165.001]
  • [Cites] J Am Coll Surg. 2006 Mar;202(3):423-30 [16500246.001]
  • [Cites] Am J Surg. 1999 Jul;178(1):50-3; discussion 54 [10456703.001]
  • [Cites] J Am Coll Surg. 1996 Jul;183(1):1-10 [8673301.001]
  • [Cites] Arch Surg. 2002 Aug;137(8):948-51; discussion 952-3 [12146996.001]
  • [Cites] N Engl J Med. 1992 Oct 1;327(14):1033 [1387700.001]
  • [Cites] Br J Surg. 2005 Jun;92(6):719-23 [15856491.001]
  • [Cites] Surg Endosc. 2001 Jan;15(1):90-3 [11178771.001]
  • [Cites] World J Surg. 2006 May;30(5):893-8 [16680605.001]
  • [Cites] Arch Surg. 1997 Aug;132(8):914-9 [9267279.001]
  • [Cites] Surg Endosc. 1999 Jan;13(1):30-4 [9869684.001]
  • [Cites] Ann Surg Oncol. 2002 Jun;9(5):480-5 [12052760.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • (PMID = 18071798.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0400874
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Wang FL, Cui SX, Sun LP, Qu XJ, Xie YY, Zhou L, Mu YL, Tang W, Wang YS: High expression of alpha 2, 3-linked sialic acid residues is associated with the metastatic potential of human gastric cancer. Cancer Detect Prev; 2009;32(5-6):437-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of alpha 2, 3-linked sialic acid residues is associated with the metastatic potential of human gastric cancer.
  • In gastric adenocarcinoma cell lines, SGC-7901, the highly metastatic cell line, displayed the most positive reaction with MAL among the selected cell lines.
  • CONCLUSION: These results suggested that high level of alpha 2, 3-linked sialic acid residues was associated with metastatic potential of gastric cancer cells.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19232843.001).
  • [ISSN] 1525-1500
  • [Journal-full-title] Cancer detection and prevention
  • [ISO-abbreviation] Cancer Detect. Prev.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Glycoconjugates; 0 / Phytohemagglutinins; 0 / Plant Lectins; 0 / leukoagglutinins, plants; GZP2782OP0 / N-Acetylneuraminic Acid
  •  go-up   go-down


43. Do YR, Song HS, Kim IH: Adrenalectomy for metastatic disease to the adrenal gland from gastric cancer: report of a case. Korean J Intern Med; 2007 Mar;22(1):18-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenalectomy for metastatic disease to the adrenal gland from gastric cancer: report of a case.
  • We report here on this case to show that for selected cases, surgical resection of adrenal metastases is feasible and this procedure may extend survival for metastatic gastric cancer patients.
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Gastrectomy. Humans. Male. Middle Aged


44. Chen HL, Chang WH, Shih SC, Pang KK, Bair MJ: Trismus and trigeminal neuralgia in one patient with colon cancer. J Natl Med Assoc; 2008 Jun;100(6):740-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Metastatic tumors to the oral cavity are relatively uncommon.
  • They are found most commonly in the mandible, and 70% of cases are adenocarcinoma-most commonly from breast and lung, followed by adrenals, kidneys, prostate, thyroid and colon.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / pathology. Mandibular Neoplasms / secondary. Trigeminal Neuralgia / etiology. Trismus / etiology

  • Genetic Alliance. consumer health - Trigeminal neuralgia.
  • MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18595580.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Wang KS, Hu ZL, Li JH, Xiao DS, Wen JF: Enhancement of metastatic and invasive capacity of gastric cancer cells by transforming growth factor-beta1. Acta Biochim Biophys Sin (Shanghai); 2006 Mar;38(3):179-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Enhancement of metastatic and invasive capacity of gastric cancer cells by transforming growth factor-beta1.
  • To investigate the effect of TGF-beta on gastric carcinoma, SGC7901, BGC823 and MKN28 (a TGF-beta-resistant cell line) adenocarcinoma clones were used.
  • After pretreatment in serum-free medium with or without 10 ng/ml TGF-beta1, their experimental metastatic potential, chemotaxis, and invasive and adhesive ability were measured.
  • These results suggested that TGF-beta1 might modulate the metastatic potential of gastric cancer cells by promoting their ability to break down and penetrate basement membrane barriers and their adhesive and motile activities.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16518542.001).
  • [ISSN] 1672-9145
  • [Journal-full-title] Acta biochimica et biophysica Sinica
  • [ISO-abbreviation] Acta Biochim. Biophys. Sin. (Shanghai)
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Fibronectins; 0 / Tgfb1 protein, mouse; 0 / Transforming Growth Factor beta; 0 / Transforming Growth Factor beta1; EC 3.4.24.- / Collagenases; EC 3.4.24.- / Gelatinases
  •  go-up   go-down


46. Kwon MS, Ko SO, Cho NP, Kim OH, Shin HK, Baek JA, Leem DH: Gastric signet-ring cell adenocarcinoma metastatic to the gingiva: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2006 Jul;102(1):62-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gastric signet-ring cell adenocarcinoma metastatic to the gingiva: a case report.

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16831674.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Jariengprasert C, Laothamatas J, Janwityanujit T, Phudhichareonrat S: Bilateral sudden sensorineural hearing loss as a presentation of metastatic adenocarcinoma of unknown primary mimicking cerebellopontine angle tumor on the magnetic resonance image. Am J Otolaryngol; 2006 Mar-Apr;27(2):143-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bilateral sudden sensorineural hearing loss as a presentation of metastatic adenocarcinoma of unknown primary mimicking cerebellopontine angle tumor on the magnetic resonance image.
  • Surgical biopsy and histopathologic finding identified masses secondary to direct invasion of adenocarcinoma of gastrointestinal origin.
  • Many investigations could not discover the primary site of the metastatic adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Cerebellar Neoplasms / diagnosis. Cerebellopontine Angle / pathology. Hearing Loss, Sensorineural / diagnosis. Magnetic Resonance Imaging

  • Genetic Alliance. consumer health - Sensorineural hearing loss.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16500481.001).
  • [ISSN] 0196-0709
  • [Journal-full-title] American journal of otolaryngology
  • [ISO-abbreviation] Am J Otolaryngol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


48. Uharcek P, Mlyncek M, Durcanský D: Appendiceal adenocarcinoma presenting with bilateral Krukenberg tumors. J Obstet Gynaecol Res; 2007 Apr;33(2):211-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Appendiceal adenocarcinoma presenting with bilateral Krukenberg tumors.
  • Primary appendiceal malignancy metastatic to the ovaries is a condition that may mimic advanced stage ovarian cancer.
  • A 52-year-old woman referred to our institution for presumed advanced stage of ovarian cancer was found to have primary appendiceal adenocarcinoma metastatic to ovaries at laparotomy.

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441899.001).
  • [ISSN] 1341-8076
  • [Journal-full-title] The journal of obstetrics and gynaecology research
  • [ISO-abbreviation] J. Obstet. Gynaecol. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


49. Ohuchida K, Mizumoto K, Miyasaka Y, Yu J, Cui L, Yamaguchi H, Toma H, Takahata S, Sato N, Nagai E, Yamaguchi K, Tsuneyoshi M, Tanaka M: Over-expression of S100A2 in pancreatic cancer correlates with progression and poor prognosis. J Pathol; 2007 Nov;213(3):275-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cell lines from metastatic sites expressed higher levels of S100A2 than those from primary sites.
  • IDC cells associated with poorly differentiated adenocarcinoma expressed higher levels of S100A2 than did IDC cells without poorly differentiated adenocarcinoma (p = 0.006).

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2007 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
  • (PMID = 17940995.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Chemotactic Factors; 0 / S100 Proteins; 0 / S100A2 protein, human
  •  go-up   go-down


50. Aiyar SE, Cho H, Lee J, Li R: Concerted transcriptional regulation by BRCA1 and COBRA1 in breast cancer cells. Int J Biol Sci; 2007 Nov 26;3(7):486-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Its expression is significantly reduced in metastatic and recurrent breast cancer, pointing to a tumor suppressor function in breast cancer development.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lancet. 2000 Dec 2;356(9245):1876-81 [11130383.001]
  • [Cites] J Biol Chem. 2003 Dec 26;278(52):52012-20 [14506230.001]
  • [Cites] IUBMB Life. 2004 Mar;56(3):161-6 [15185750.001]
  • [Cites] Oncogene. 2004 Jul 8;23(31):5316-29 [15107825.001]
  • [Cites] Genes Dev. 2004 Sep 1;18(17):2134-46 [15342491.001]
  • [Cites] Bull Cancer. 1992;79(3):261-70 [1392165.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 May 27;94(11):5605-10 [9159119.001]
  • [Cites] Nucleic Acids Res. 1998 Feb 1;26(3):847-53 [9443979.001]
  • [Cites] Genes Dev. 1998 Feb 1;12(3):343-56 [9450929.001]
  • [Cites] Nat Genet. 1998 Jul;19(3):254-6 [9662397.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):44-8 [9988231.001]
  • [Cites] Cell. 1999 Apr 2;97(1):41-51 [10199401.001]
  • [Cites] Science. 1999 May 21;284(5418):1354-6 [10334989.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):495-503 [10408859.001]
  • [Cites] Science. 1999 Sep 3;285(5433):1576-9 [10477523.001]
  • [Cites] Mod Pathol. 2005 Oct;18(10):1295-304 [15976813.001]
  • [Cites] Ann Oncol. 2005 Nov;16(11):1846-7 [15972278.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):1199-207 [16424059.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):807-12 [16467092.001]
  • [Cites] J Clin Oncol. 2006 May 20;24(15):2261-7 [16636340.001]
  • [Cites] Clin Exp Metastasis. 2007;24(1):13-23 [17295094.001]
  • [Cites] Oncogene. 2007 Apr 19;26(18):2543-53 [17043641.001]
  • [Cites] J Cell Biochem. 2008 Apr 15;103(6):1798-807 [17910036.001]
  • [Cites] Cell. 2001 Mar 9;104(5):743-53 [11257228.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9587-92 [11493692.001]
  • [Cites] J Cell Biol. 2001 Dec 10;155(6):911-21 [11739404.001]
  • [Cites] Mol Cell Biol. 2002 May;22(9):2918-27 [11940650.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 3;94(13):990-1000 [12096084.001]
  • [Cites] Mol Cell Biol. 2003 Mar;23(6):1863-73 [12612062.001]
  • [Cites] Oncogene. 2003 May 1;22(17):2680-8 [12730682.001]
  • [Cites] Am J Obstet Gynecol. 2003 Jul;189(1):59-65 [12861139.001]
  • [Cites] Bioinformatics. 2003 Oct 12;19(15):1945-51 [14555628.001]
  • [Cites] APMIS. 2003 Nov;111(11):1027-36 [14629269.001]
  • [Cites] J Invest Dermatol. 2004 Feb;122(2):369-80 [15009718.001]
  • (PMID = 18071589.001).
  • [ISSN] 1449-2288
  • [Journal-full-title] International journal of biological sciences
  • [ISO-abbreviation] Int. J. Biol. Sci.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA093506; United States / NIDDK NIH HHS / DK / R01 DK064604; United States / NCI NIH HHS / CA / CA93506; United States / NIDDK NIH HHS / DK / DK064604
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / BRCA1 Protein; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / negative elongation factor
  • [Other-IDs] NLM/ PMC2096739
  • [Keywords] NOTNLM ; BRCA1 / COBRA1 / breast cancer. / shRNA knockdown / transcription regulation
  •  go-up   go-down


51. Pozzi EC, Altermatt HJ, Rees TD, Bornstein MM: Exophytic mass of the gingiva as the first manifestation of metastatic pulmonary adenocarcinoma. J Periodontol; 2008 Jan;79(1):187-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exophytic mass of the gingiva as the first manifestation of metastatic pulmonary adenocarcinoma.
  • METHODS: The clinicopathologic features of a gingival metastasis originating from lung adenocarcinoma in a female patient are described.
  • Finally, a biopsy of the lungs confirmed a poorly differentiated adenocarcinoma with multiple metastases, including the oral cavity.
  • CONCLUSIONS: An exophytic lesion on the gingiva can be the first sign of metastatic adenocarcinoma to the oral mucosa.
  • [MeSH-major] Adenocarcinoma / secondary. Gingival Neoplasms / secondary. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18166110.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Keratin-7; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


52. Zhu X, Leaw J, Gu W, Qian Y, Du H, Wang B, Hong X, Yin J: Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin. J Cancer Res Clin Oncol; 2008 Sep;134(9):929-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II clinical trial of advanced and metastatic gastric cancer based on continuous infusion of 5-fluorouracil combined with epirubicin and oxaliplatin.
  • PURPOSE: To evaluate the efficacy and tolerability of systematic treatment of unresectable advanced or metastatic gastric cancer (A/MGC) based on EOF5 regimen (the combination of epirubicin, oxaliplatin and 5-day continuous infusion of 5-fluorouracil).
  • PATIENTS AND METHODS: Twenty-six patients (18 males, 8 females; age range, 35-72 years) with histologically confirmed metastatic (n = 23) or unresectable advanced (n = 3) gastric adenocarcinoma with (n = 6) or without previous chemotherapy (n = 20) were consented to receive EOF5 (epirubicin 50 mg/m(2) and oxaliplatin 130 mg/m(2) on day 1, followed by continuous infusion of 5-fluorouracil 375-425 mg/m(2) day(-1) on day 1-5), and the treatment cycle was repeated every 3 weeks.

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Gastroenterol. 2006 Jan 7;12(1):17-20 [16440411.001]
  • [Cites] Cancer Res. 1993 Dec 15;53(24):5970-6 [8261411.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):54-9 [12506170.001]
  • [Cites] Ann Oncol. 2000 Mar;11(3):301-6 [10811496.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Br J Cancer. 2005 Jul 25;93(2):190-4 [16012522.001]
  • [Cites] J Clin Oncol. 2000 Jul;18(14):2648-57 [10894863.001]
  • [Cites] Toxicol Lett. 1998 Dec 28;102-103:227-34 [10022258.001]
  • [Cites] Br J Cancer. 2005 May 9;92(9):1644-9 [15856038.001]
  • [Cites] Ann Oncol. 1994 Sep;5(7):609-16 [7993836.001]
  • [Cites] Ann Oncol. 2003 Mar;14(3):383-7 [12598342.001]
  • [Cites] J Clin Oncol. 2002 Dec 1;20(23):4543-8 [12454110.001]
  • [Cites] Br J Cancer. 1999 Apr;80(1-2):269-72 [10390007.001]
  • [Cites] Cancer. 1999 Jan 15;85(2):295-301 [10023695.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1694-9 [8625036.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3560-8 [10550155.001]
  • [Cites] J Clin Oncol. 2004 Feb 15;22(4):658-63 [14966088.001]
  • [Cites] Cancer Chemother Pharmacol. 1990;25(4):299-303 [2295116.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Apr 1;47(1):13-47 [10758303.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):1996-2004 [11956258.001]
  • [Cites] Ann Oncol. 2005 Sep;16(9):1488-97 [15939717.001]
  • [Cites] Cancer. 1996 May 15;77(10):1978-85 [8640659.001]
  • [Cites] Anticancer Drugs. 1997 Oct;8(9):876-85 [9402315.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • (PMID = 18343948.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 3Z8479ZZ5X / Epirubicin; U3P01618RT / Fluorouracil
  •  go-up   go-down


53. Massoud W, Paparel P, Lopez JG, Perrin P, Daumont M, Ruffion A: Discovery of a pituitary adenoma following treatment with a gonadotropin-releasing hormone agonist in a patient with prostate cancer. Int J Urol; 2006 Jan;13(1):87-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Hormone therapy represents a prominent branch in the treatment of locally advanced and metastatic prostate cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenoma / chemically induced. Antineoplastic Agents, Hormonal / adverse effects. Gonadotropin-Releasing Hormone / agonists. Leuprolide / adverse effects. Pituitary Neoplasms / chemically induced. Prostatic Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Pituitary cancer.
  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Hazardous Substances Data Bank. LEUPROLIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16448441.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 33515-09-2 / Gonadotropin-Releasing Hormone; EFY6W0M8TG / Leuprolide
  •  go-up   go-down


54. Chadha AS, Ganti AK, Sohi JS, Sahmoun AE, Mehdi SA: Survival in untreated early stage non-small cell lung cancer. Anticancer Res; 2005 Sep-Oct;25(5):3517-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients were Caucasian and 66.7% had stage I disease, 46.2% had squamous cell carcinoma, while adenocarcinoma was found in 28.2%.
  • The major reason for non treatment was chronic obstructive pulmonary disease (64.1%) and the main cause of death was metastatic disease (48.7%).


55. Cartwright T, McCollum D, Boehm KA: Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer. Am J Clin Oncol; 2010 Jun;33(3):307-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dosing considerations for capecitabine-irinotecan regimens in the treatment of metastatic and/or locally advanced colorectal cancer.
  • Capecitabine (Xeloda), Roche Laboratories Inc., Nutley, NJ) is an orally administered fluoropyrimidine carbamate that serves as a prodrug of 5-fluorouracil (5-FU), an integral component of chemotherapy (CT) regimens for metastatic colorectal cancer (mCRC).
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colorectal Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20375835.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol; XELOX
  • [Number-of-references] 53
  •  go-up   go-down


56. Yuan ZF, Shi HR, Sun HM, Li WC: [Detection of CDX-2, CK7 and CK20 in primary and metastatic ovarian carcinoma]. Zhonghua Bing Li Xue Za Zhi; 2007 Aug;36(8):555-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detection of CDX-2, CK7 and CK20 in primary and metastatic ovarian carcinoma].
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Colonic Neoplasms / metabolism. Colonic Neoplasms / pathology. Cystadenocarcinoma, Mucinous / metabolism. Cystadenocarcinoma, Mucinous / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Diagnosis, Differential. Female. Humans. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17980105.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Homeodomain Proteins; 0 / Keratin-20; 0 / Keratin-7; 0 / Trans-Activators; 156560-97-3 / Cdx-2-3 protein
  •  go-up   go-down


57. Horwhat JD, Gerke H, Acosta RD, Pavey DA, Jowell PS: Focal or diffuse "fullness" of the pancreas on CT. Usually benign, but EUS plus/minus FNA is warranted to identify malignancy. JOP; 2009;10(1):37-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: FNA was performed in 19/69 (27.5%) with 4 new diagnoses of pancreatic adenocarcinoma, one metastatic renal cell carcinoma, one metastatic colon cancer, one chronic pancreatitis and 12 benign results.


58. Lavasani L, Zapanta PE, Tanna N, Sadeghi N: Metastasis of prostatic adenocarcinoma to the sphenoid sinus. Ann Otol Rhinol Laryngol; 2006 Sep;115(9):690-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastasis of prostatic adenocarcinoma to the sphenoid sinus.
  • The presentation, diagnosis, and management of prostatic adenocarcinoma metastatic to the sphenoid sinus are reviewed.
  • A 67-year-old man with a history of prostatic adenocarcinoma presented with gradual left visual loss.
  • Operative biopsy of the lesion was significant for adenocarcinoma of the prostate.
  • Furthermore, the pathophysiology and potential routes of metastatic disease should be assessed for these primary neoplasms.
  • Having a high level of suspicion for metastatic disease from specific primary sites will help guide the pathological evaluation.
  • As in this clinical scenario of a patient with a history of prostatic adenocarcinoma, appropriate analysis would entail sending specimens for immunohistochemical staining, such as prostate-specific antigen and prostate-specific acid phosphatase.
  • [MeSH-major] Adenocarcinoma / pathology. Paranasal Sinus Neoplasms / secondary. Prostatic Neoplasms / pathology. Sphenoid Sinus / pathology

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17044541.001).
  • [ISSN] 0003-4894
  • [Journal-full-title] The Annals of otology, rhinology, and laryngology
  • [ISO-abbreviation] Ann. Otol. Rhinol. Laryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


59. Zamboni M, Lannes DC, Cordeiro Pde B, Toscano E, Torquato EB, Cordeiro SS, Cavalcanti A: Transthoracic biopsy with core cutting needle (Trucut) for the diagnosis of mediastinal tumors. Rev Port Pneumol; 2009 Jul-Aug;15(4):589-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Percutaneous core cutting needle biopsy established a specific histological diagnosis in 88% of the patients: 23/56 (41%) lymphomas; 12/56 (21%) thymomas; 5/56 (3%) thymic carcinomas; 3/56 (2%) small cell carcinoma and 1/56 (0.6%) metastatic adenocarcinoma, metastatic squamous cell carcinoma, neuroendocrine primitive carcinoma, plasmocytoma, teratoma and goiter.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19547893.001).
  • [ISSN] 2172-6825
  • [Journal-full-title] Revista portuguesa de pneumologia
  • [ISO-abbreviation] Rev Port Pneumol
  • [Language] eng; por
  • [Publication-type] Journal Article
  • [Publication-country] Portugal
  •  go-up   go-down


60. Jeng YM, Wang TH, Lu SH, Yuan RH, Hsu HC: Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma. Br J Surg; 2009 Jan;96(1):66-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic significance of insulin-like growth factor II mRNA-binding protein 3 expression in gastric adenocarcinoma.
  • The aim was to establish the prognostic value of IMP-3 expression in gastric adenocarcinoma.
  • CONCLUSION: IMP-3 expression correlates with the metastatic potential of gastric adenocarcinoma and is an independent prognostic factor.
  • [MeSH-major] Adenocarcinoma / metabolism. Insulin-Like Growth Factor Binding Protein 2 / metabolism. Insulin-Like Growth Factor Binding Protein 3 / metabolism. Stomach Neoplasms / metabolism

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2008 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 19109797.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Insulin-Like Growth Factor Binding Protein 2; 0 / Insulin-Like Growth Factor Binding Protein 3; 0 / RNA, Messenger
  •  go-up   go-down


61. Kim HJ, Lee KW, Kim YJ, Oh DY, Kim JH, Im SA, Lee JS: Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer. Acta Oncol; 2009;48(3):385-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy-induced transient CEA and CA19-9 surges in patients with metastatic or recurrent gastric cancer.
  • However, we have observed a transient increase in carcinoembryonic antigen (CEA) or carbohydrate antigen 19-9 (CA19-9) levels despite clinical benefits from chemotherapy in patients with metastatic or recurrent gastric cancer (MRGC).
  • [MeSH-minor] Adenocarcinoma / blood. Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Disease Progression. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18855156.001).
  • [ISSN] 1651-226X
  • [Journal-full-title] Acta oncologica (Stockholm, Sweden)
  • [ISO-abbreviation] Acta Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Norway
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


62. Nishide N, Kanamura N: The value of carcinoembryonic antigen staining to determine the primary malignancy in metastatic carcinoma to the gingiva. Am J Clin Oncol; 2006 Jun;29(3):316-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of carcinoembryonic antigen staining to determine the primary malignancy in metastatic carcinoma to the gingiva.
  • [MeSH-major] Adenocarcinoma / secondary. Carcinoembryonic Antigen / analysis. Gingival Neoplasms / secondary. Neoplasms, Second Primary / pathology. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16755187.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carcinoembryonic Antigen
  •  go-up   go-down


63. Mantha A, Legnani FG, Bagley CA, Gallia GL, Garonzik I, Pradilla G, Amundson E, Tyler BM, Brem H, Gokaslan ZL: A novel rat model for the study of intraosseous metastatic spine cancer. J Neurosurg Spine; 2005 Mar;2(3):303-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A novel rat model for the study of intraosseous metastatic spine cancer.
  • OBJECT: Although metastatic spinal disease constitutes a significant percentage of all spinal column tumors, an accessible and reproducible animal model has not been reported.
  • Group 1 animals underwent a transabdominal exposure and implantation of CRL-1666 breast adenocarcinoma into the L-6 vertebral body (VB).
  • This new rat model allows for the preclinical evaluation of novel therapeutic treatments for patients harboring metastatic spine disease.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15796355.001).
  • [ISSN] 1547-5654
  • [Journal-full-title] Journal of neurosurgery. Spine
  • [ISO-abbreviation] J Neurosurg Spine
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Liu Z, Bai Y, Li Y, Ohba K, Nakamura H, Ozaki T, Taniguchi E, Mori I, Kakudo K: Non-solid type thyroid carcinoma: a case report of moderately differentiated adenocarcinoma of the thyroid. Pathol Int; 2010 Jul;60(7):524-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-solid type thyroid carcinoma: a case report of moderately differentiated adenocarcinoma of the thyroid.
  • Immunohistochemistry revealed high a MIB-1 labeling index (15-20%) in both the primary tumor and the metastatic tumor in the lymph nodes. p53 immunoreaction was found positive at very low level (<5%).
  • E-cadherin was faintly positive in a few cells of the primary tumor and negative in the metastatic site.
  • We recently proposed a new classification for follicular cell tumors of the thyroid gland, and this case is an example of moderately-differentiated adenocarcinoma according to our classification.
  • [MeSH-major] Adenocarcinoma, Papillary / pathology. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20594275.001).
  • [ISSN] 1440-1827
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Iodine Radioisotopes
  •  go-up   go-down


65. Zingg U, Divalentino D, McQuinn A, Mardzuki A, Thompson SK, Karapetis CS, Watson DI: Outcome for esophageal cancer following treatment with chemotherapy and radiotherapy but not esophagectomy: Nonsurgical treatment of esophageal cancer. Clin Exp Gastroenterol; 2009;2:75-83
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Seventy-five patients were treated for localized disease, and 52 for metastatic disease at diagnosis.
  • Except for age, which was higher in patients without metastases, there were no significant differences between the patients with vs. without metastatic disease.
  • No significant difference between adenocarcinoma and squamous cell carcinoma was identified.
  • CONCLUSION: In patients with localized disease at diagnosis, long-term survival can be achieved in some patients, whereas five-year survival is rare in patients who present with metastatic disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1999 May 5;281(17):1623-7 [10235156.001]
  • [Cites] J Support Oncol. 2006 Sep;4(8):365-73, 379 [17004508.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1407-10 [11762812.001]
  • [Cites] Eur J Cancer. 2002 Jan;38(2):300-13 [11803146.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 May 1;53(1):134-9 [12007951.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1662-9 [12444180.001]
  • [Cites] J Clin Oncol. 2003 Jul 15;21(14):2697-702 [12860946.001]
  • [Cites] N Engl J Med. 2003 Dec 4;349(23):2241-52 [14657432.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23(10):2310-7 [15800321.001]
  • [Cites] World J Surg. 2006 Feb;30(2):183-90 [16425075.001]
  • [Cites] Br J Cancer. 2007 Feb 12;96(3):432-8 [17245338.001]
  • [Cites] J Clin Oncol. 2007 Apr 1;25(10):1160-8 [17401004.001]
  • [Cites] Ann Surg. 2007 May;245(5):717-25 [17457164.001]
  • [Cites] Acta Oncol. 2007;46(8):1070-4 [17851842.001]
  • [Cites] Ann Surg Oncol. 2008 Feb;15(2):576-82 [18057993.001]
  • [Cites] Aliment Pharmacol Ther. 2008 Mar 1;27(5):385-95 [18081735.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2008 Feb;20(1):53-60 [18345545.001]
  • [Cites] Ann Surg Oncol. 2008 Jun;15(6):1577-84 [18379852.001]
  • [Cites] J Thorac Oncol. 2008 May;3(5):516-20 [18449005.001]
  • [Cites] Oncology. 2007;73(5-6):328-34 [18497505.001]
  • [Cites] Dis Esophagus. 2008;21(8):697-703 [18522639.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):261-7 [8996151.001]
  • [Cites] Am J Clin Oncol. 1998 Oct;21(5):462-5 [9781600.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):18-24 [12556953.001]
  • [Cites] Clin Oncol (R Coll Radiol). 2003 May;15(3):109-14 [12801046.001]
  • [Cites] Radiother Oncol. 2007 May;83(2):139-47 [17445928.001]
  • [Cites] J Thorac Oncol. 2007 Jun;2(6):553-68 [17545853.001]
  • [Cites] Ann Surg. 2004 Dec;240(6):962-72; discussion 972-4 [15570202.001]
  • [Cites] Ann Surg. 2005 Nov;242(5):684-92 [16244542.001]
  • [Cites] Ann Oncol. 2006 Jan;17(1):29-34 [16303863.001]
  • [Cites] World J Gastroenterol. 2006 Jul 14;12(26):4185-90 [16830371.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2915-21 [10561371.001]
  • (PMID = 21694830.001).
  • [ISSN] 1178-7023
  • [Journal-full-title] Clinical and experimental gastroenterology
  • [ISO-abbreviation] Clin Exp Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] New Zealand
  • [Other-IDs] NLM/ PMC3108630
  • [Keywords] NOTNLM ; chemoradiotherapy / esophageal cancer / metastases / nonsurgical treatment / survival
  •  go-up   go-down


66. Grande M, Facchini F, La Rosa M, Pozzoli GL, Leone M, Piana S, Monica B: [Carcinoma of the collecting ducts of Bellini: a case report with cutaneous metastasis as the initial clinical manifestation]. Urologia; 2010 Jan-Mar;77 Suppl 16:51-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Bellini's collecting ducts carcinoma represents a rare tumor with an aggressive behaviour with a poor prognosis and often metastatic at diagnosis.
  • RESULTS: After reporting an histopathologic finding of cutaneous metastasis of unknown origin adenocarcinoma with poorly differentiation, a voluminous 6 cm left mesorenal mass is diagnosed through uro-CT.
  • CONCLUSIONS: Most of Bellini’s carcinoma are already metastatic at presentation.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21104663.001).
  • [ISSN] 1724-6075
  • [Journal-full-title] Urologia
  • [ISO-abbreviation] Urologia
  • [Language] ita
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


67. Willeke F, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, Grobholz R, Willer A, Kähler G, Post S, Hofheinz RD: A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer; 2007 Mar 26;96(6):912-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Three-year overall survival for all patients with surgery (excluding three patients treated for local relapse or with primary metastatic disease) was 80%.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Rectal Neoplasms / drug therapy. Rectal Neoplasms / radiotherapy

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Pathol Lab Med. 2000 Jul;124(7):1016-25 [10888778.001]
  • [Cites] Oncology (Williston Park). 2000 Dec;14(12 Suppl 14):56-9 [11200151.001]
  • [Cites] N Engl J Med. 2001 Aug 30;345(9):638-46 [11547717.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] N Engl J Med. 2004 Oct 21;351(17):1731-40 [15496622.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1350-7 [15684318.001]
  • [Cites] Br J Cancer. 2005 Apr 11;92(7):1215-20 [15785742.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):4856-65 [15939923.001]
  • [Cites] Br J Radiol. 2005 Oct;78(934):934-8 [16177017.001]
  • [Cites] Ann Oncol. 2005 Dec;16(12):1898-905 [16219623.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8688-96 [16246976.001]
  • [Cites] Ann Oncol. 2006 Mar;17(3):361-71 [16500912.001]
  • [Cites] Br J Cancer. 2006 Apr 10;94(7):976-81 [16552435.001]
  • (PMID = 17325705.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  • [Other-IDs] NLM/ PMC2360100
  •  go-up   go-down


68. Bassarak N, Blankenstein T, Brüning A, Dian D, Bergauer F, Friese K, Mylonas I: Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium? BMC Cancer; 2010;10:224
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is lymphadenectomy a prognostic marker in endometrioid adenocarcinoma of the human endometrium?
  • Although lymph node metastases are important prognostic parameters, it has been contentious whether a pelvic lymph node dissection itself has a prognostic impact in the treatment of endometrial cancer, especially in endometrioid adenocarcinoma.
  • Therefore, this study evaluated whether lymphadenectomy has a prognostic impact in patients with endometrioid adenocarcinoma.
  • METHODS: The benefits of lymphadenectomy were examined in 214 patients with a histological diagnosis of endometrial adenocarcinoma.
  • RESULTS: Of the 214 patients with endometrial adenocarcinoma, 171 (79.9%) were classified as FIGO stage I, 15 (7.0%) FIGO stage II, 21 (9.8%) FIGO stage III and 7 (3.3%) FIGO stage IV.
  • Only 11 (5.1%) patients showed metastatic disease in the lymph nodes.
  • CONCLUSIONS: The performance of an operative lymphadenectomy resulted in better survival of patients with endometrioid adenocarcinoma.
  • Therefore, even in endometrioid adenocarcinoma, a pelvic and/or para-aortic lymphadenectomy should be performed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2001 Feb;80(2):139-44 [11161851.001]
  • [Cites] Eur J Cancer. 2009 May;45(7):1304-14 [19231155.001]
  • [Cites] Oncologist. 2003;8(6):541-52 [14657533.001]
  • [Cites] Gynecol Oncol. 2003 Dec;91(3):518-25 [14675670.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):649-62 [15188130.001]
  • [Cites] Anticancer Res. 2004 May-Jun;24(3b):2073-8 [15274403.001]
  • [Cites] Cancer. 1987 Oct 15;60(8 Suppl):2035-41 [3652025.001]
  • [Cites] Gynecol Oncol. 1991 Jan;40(1):55-65 [1989916.001]
  • [Cites] Gynecol Oncol. 1995 Jan;56(1):29-33 [7821843.001]
  • [Cites] Am J Obstet Gynecol. 1997 Apr;176(4):777-88; discussion 788-9 [9125601.001]
  • [Cites] J Clin Oncol. 2005 Jun 1;23(16):3668-75 [15738538.001]
  • [Cites] Gynecol Oncol. 2006 Jul;102(1):92-7 [16406063.001]
  • [Cites] Int J Gynaecol Obstet. 2006 Nov;95 Suppl 1:S105-43 [17161155.001]
  • [Cites] Gynecol Oncol. 2007 Apr;105(1):150-6 [17197012.001]
  • [Cites] Eur J Cancer. 2007 Nov;43(16):2434-44 [17911007.001]
  • [Cites] Int J Gynecol Cancer. 2008 Mar-Apr;18(2):255-61 [17624991.001]
  • [Cites] Am J Obstet Gynecol. 2008 Apr;198(4):457.e1-5; discussion 457.e5-6 [18395039.001]
  • [Cites] Acta Obstet Gynecol Scand. 2008;87(12):1361-9 [18951214.001]
  • [Cites] Lancet. 2009 Jan 10;373(9658):125-36 [19070889.001]
  • [Cites] Gynakol Geburtshilfliche Rundsch. 2003 Apr;43(2):104-10 [12649583.001]
  • (PMID = 20492712.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2891635
  •  go-up   go-down


69. Clarke LE, Seykora JT: Primary cutaneous adenomyoepithelioma. J Cutan Pathol; 2007 Aug;34(8):654-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This rare tumor may mimic malignant lesions including metastatic adenocarcinoma.

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640238.001).
  • [ISSN] 0303-6987
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


70. Sergeant G, Penninckx F, Topal B: Quantitative RT-PCR detection of colorectal tumor cells in peripheral blood--a systematic review. J Surg Res; 2008 Nov;150(1):144-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Twenty percent to 40% of patients with node-negative colorectal cancer die of metastatic disease.
  • [MeSH-major] Adenocarcinoma / blood. Colorectal Neoplasms / blood. Neoplasm Metastasis / diagnosis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18621394.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 73
  •  go-up   go-down


71. McGrath S, Cross S, Pritchard SA: Histopathological assessment of lymph nodes in upper gastrointestinal cancer: does triple levelling detect significantly more metastases? J Clin Pathol; 2007 Nov;60(11):1222-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: For cancers of the upper gastrointestinal tract it is standard to examine one section/level, from paraffin blocks containing lymph node tissue, for metastatic tumour.
  • CONCLUSIONS: Examining lymph nodes at three levels did detect more metastatic deposits than examination of one section/level.
  • [MeSH-major] Adenocarcinoma / secondary. Esophageal Neoplasms / pathology. Lymphatic Metastasis / diagnosis. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1999 Nov 1;86(9):1883-5 [10547564.001]
  • [Cites] Am J Clin Oncol. 2006 Jun;29(3):298-304 [16755184.001]
  • [Cites] Hepatogastroenterology. 2000 May-Jun;47(33):728-32 [10919020.001]
  • [Cites] Ann Surg. 2000 Sep;232(3):353-61 [10973385.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1874-82 [11064343.001]
  • [Cites] Br J Surg. 2001 Mar;88(3):426-32 [11260111.001]
  • [Cites] Ann Surg. 2001 Sep;234(3):360-7; discussion 368-9 [11524589.001]
  • [Cites] Dig Liver Dis. 2001 Oct;33(7):534-8 [11816540.001]
  • [Cites] J Surg Oncol. 2002 Apr;79(4):224-9 [11920779.001]
  • [Cites] Cancer. 2002 Oct 1;95(7):1434-43 [12237911.001]
  • [Cites] Ann Surg Oncol. 2002 Oct;9(8):771-4 [12374660.001]
  • [Cites] J Surg Oncol. 2003 Jan;82(1):19-27 [12501165.001]
  • [Cites] Br J Surg. 2003 Dec;90(12):1522-30 [14648731.001]
  • [Cites] J Clin Pathol. 2004 Nov;57(11):1165-7 [15509677.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Arch Pathol Lab Med. 1997 Sep;121(9):925-9 [9302923.001]
  • [Cites] J Gastrointest Surg. 1999 Sep-Oct;3(5):468-76 [10482702.001]
  • [Cites] J Clin Pathol. 2000 Feb;53(2):89-94 [10767821.001]
  • (PMID = 17298984.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2095474
  •  go-up   go-down


72. Khosravi Shahi P, Díaz Muñoz de la Espada VM: [Pancreatic adenocarcinoma: therapeutical update]. An Med Interna; 2005 Aug;22(8):390-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pancreatic adenocarcinoma: therapeutical update].
  • [Transliterated title] Adenocarcinoma de páncreas: actualizaciones terapéuticas.
  • Because of difficulties in diagnosis, the aggressiveness of pancreatic cancers, and the lack of effective systemic therapies, generally fewer than 5% of patients with adenocarcinoma of the pancreas survive 5 years after diagnosis.
  • The median survival in metastatic pancreatic cancer is nearly six months.Today, surgery remains the only curative therapeutic option, and the standard treatment in patients with advanced disease is gemcitabine.
  • [MeSH-major] Adenocarcinoma / therapy. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351494.001).
  • [ISSN] 0212-7199
  • [Journal-full-title] Anales de medicina interna (Madrid, Spain : 1984)
  • [ISO-abbreviation] An Med Interna
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Number-of-references] 37
  •  go-up   go-down


73. Prawettongsopon C, Asawakarn S, Suthiphongchai T: Suppression of prometastatic phenotype of highly metastatic androgen-independent rat prostate cancer MLL cell line by PI3K inhibitor LY294002. Oncol Res; 2009;17(7):301-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of prometastatic phenotype of highly metastatic androgen-independent rat prostate cancer MLL cell line by PI3K inhibitor LY294002.
  • Inhibition of PI3K by LY294002 suppressed cell invasion and motility of the highly metastatic androgen-independent Dunning rat prostate cancer MLL cell line with similar IC50 values and inhibition profile.
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Animals. Cell Movement / drug effects. Extracellular Signal-Regulated MAP Kinases / metabolism. Male. Matrix Metalloproteinase 2 / genetics. Matrix Metalloproteinase 2 / metabolism. Phosphorylation / drug effects. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Reverse Transcriptase Polymerase Chain Reaction. Signal Transduction. Tumor Cells, Cultured. Urokinase-Type Plasminogen Activator / genetics. Urokinase-Type Plasminogen Activator / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19408575.001).
  • [ISSN] 0965-0407
  • [Journal-full-title] Oncology research
  • [ISO-abbreviation] Oncol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgens; 0 / Chromones; 0 / Enzyme Inhibitors; 0 / Morpholines; 0 / RNA, Messenger; 154447-36-6 / 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 3.4.21.73 / Urokinase-Type Plasminogen Activator; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


74. Ho V, Whiteman D, Miller M, Raulli A, Ombiga J, Boyd P: Esophageal cancer in Indigenous Australians in Far North Queensland. J Gastroenterol Hepatol; 2009 Oct;24(10):1683-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among patients with esophageal squamous cell cancer, Indigenous patients were more likely than non-Indigenous patients to present with metastatic disease (P = 0.0271) at a younger mean age (50.7 years vs 67.2 years; P = 0.0002).
  • Indigenous persons tend to present at a younger age and with metastatic disease.
  • [MeSH-major] Adenocarcinoma / ethnology. Carcinoma, Squamous Cell / ethnology. Esophageal Neoplasms / ethnology. Health Status Disparities. Oceanic Ancestry Group / statistics & numerical data


75. Deegan CA, Murray D, Doran P, Ecimovic P, Moriarty DC, Buggy DJ: Effect of anaesthetic technique on oestrogen receptor-negative breast cancer cell function in vitro. Br J Anaesth; 2009 Nov;103(5):685-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Metastatic recurrence is the main cause of breast cancer-related deaths.
  • Tumour cell proliferation and migration are crucial steps in the metastatic process.
  • Several perioperative factors, including general anaesthesia and opioid analgesia, adversely affect immune function, potentially increasing metastatic recurrence.
  • [MeSH-major] Adenocarcinoma / pathology. Anesthesia / methods. Anesthetics, Inhalation / pharmacology. Anesthetics, Intravenous / pharmacology. Breast Neoplasms / pathology

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Anesthesia.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. PROPOFOL .
  • Hazardous Substances Data Bank. Sevoflurane .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Br J Anaesth. 2010 Apr;104(4):516
  • (PMID = 19776028.001).
  • [ISSN] 1471-6771
  • [Journal-full-title] British journal of anaesthesia
  • [ISO-abbreviation] Br J Anaesth
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Anesthetics, Inhalation; 0 / Anesthetics, Intravenous; 0 / Methyl Ethers; 0 / Receptors, Estrogen; 38LVP0K73A / sevoflurane; YI7VU623SF / Propofol
  •  go-up   go-down


76. Shimamura T, Royal RE, Kioi M, Nakajima A, Husain SR, Puri RK: Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma. Cancer Res; 2007 Oct 15;67(20):9903-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-4 cytotoxin therapy synergizes with gemcitabine in a mouse model of pancreatic ductal adenocarcinoma.
  • Here, we show the efficacy of the combination therapy of gemcitabine with an interleukin-4 (IL-4) cytotoxin composed of IL-4 and truncated Pseudomonas exotoxin in animal models of pancreatic ductal adenocarcinoma (PDA).
  • To confirm synergistic antitumor activity in vivo and monitor precise real-time disease progression, we used a novel metastatic and orthotopic mouse model using green fluorescent protein-transfected cancer cells and whole-body imaging system.
  • In addition, combined treatment significantly prolonged the survival of nude mice bearing day 14 advanced distant metastatic PDA tumors.

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17942922.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Leukocidins; 0 / Pseudomonas aeruginosa Cytotoxins; 0 / Receptors, Interleukin-4; 0 / Recombinant Fusion Proteins; 0W860991D6 / Deoxycytidine; 147336-22-9 / Green Fluorescent Proteins; 207137-56-2 / Interleukin-4; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


77. Subramanya D, Grivas PD, Styler M: Appendiceal carcinoma: a diagnostic and therapeutic challenge. Postgrad Med; 2008 Nov;120(4):95-100
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, treatment should be individualized based on patient-specific parameters, such as the presence of comorbidities, performance status, as well as the presence of metastatic disease.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Adenocarcinoma, Mucinous / surgery. Appendiceal Neoplasms / diagnosis. Appendiceal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19020371.001).
  • [ISSN] 1941-9260
  • [Journal-full-title] Postgraduate medicine
  • [ISO-abbreviation] Postgrad Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


78. Tokai H, Kawashita Y, Eguchi S, Kamohara Y, Takatsuki M, Okudaira S, Tajima Y, Hayashi T, Kanematsu T: A case of mucin producing liver metastases with intrabiliary extension. World J Gastroenterol; 2006 Aug 14;12(30):4918-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He underwent right hemicolectomy for cecal cancer eight years ago, and had a metastatic liver tumor in segment 8 (S8), which was surgically resected about 4 years after the initial operation.
  • Histopathological examination of the resected specimens from both operations revealed a well-differentiated adenocarcinoma with mucinous carcinoma.
  • With a tentative diagnosis of a recurrence of metastatic cancer, partial hepatectomy of S8 was performed.
  • Histological examination of the resected specimens also revealed mucinous adenocarcinoma, which had invaded into the biliary ducts, replacing and extending along its epithelium.
  • Therefore, the tumor was diagnosed as a metastatic adenocarcinoma from colonic cancer.
  • Liver metastases of colorectal adenocarcinoma sometimes invade the Glisson's triad and grow along the biliary ducts.
  • [MeSH-major] Adenocarcinoma. Bile Duct Neoplasms / metabolism. Bile Duct Neoplasms / secondary. Colonic Neoplasms / pathology. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Mucins / metabolism

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2004 Jan;39(1):72-5 [14767739.001]
  • [Cites] World J Gastroenterol. 2003 Feb;9(2):193-200 [12532430.001]
  • [Cites] AJR Am J Roentgenol. 1981 Feb;136(2):345-8 [6258409.001]
  • [Cites] Radiology. 1981 Dec;141(3):733-6 [6272354.001]
  • [Cites] Surgery. 1986 Aug;100(2):278-84 [3526605.001]
  • [Cites] World J Surg. 1987 Aug;11(4):541-7 [3630198.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):74-8 [7826164.001]
  • [Cites] Dis Colon Rectum. 1996 Aug;39(8):847-51 [8756838.001]
  • [Cites] Jpn J Clin Oncol. 1997 Feb;27(1):18-21 [9070335.001]
  • [Cites] Am J Surg. 1997 Jun;173(6):467-71 [9207156.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):171-7 [9921990.001]
  • [Cites] Ann Surg. 2005 May;241(5):715-22, discussion 722-4 [15849507.001]
  • [Cites] Surgery. 1999 Nov;126(5):829-34 [10568181.001]
  • [Cites] Am J Surg Pathol. 2000 Jun;24(6):870-6 [10843291.001]
  • [Cites] Pathol Int. 2002 Aug;52(8):514-8 [12366810.001]
  • [Cites] AJR Am J Roentgenol. 1978 Nov;131(5):839-42 [101040.001]
  • (PMID = 16937483.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Mucins
  • [Other-IDs] NLM/ PMC4087635
  •  go-up   go-down


79. Bagwan IN, Taylor A, Dina R: Metastatic apocrine carcinoma of female genital tract. J Clin Pathol; 2009 Mar;62(3):287-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic apocrine carcinoma of female genital tract.
  • [MeSH-major] Adenocarcinoma / secondary. Vulvar Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19251959.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  •  go-up   go-down


80. Wang L, Ma J, Liu F, Yu Q, Chu G, Perkins AC, Li Y: Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance. Gynecol Oncol; 2007 Jun;105(3):695-702
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance.
  • The objective of this study was to evaluate the patterns of MUC1 expression in primary tumors and metastatic lesions in the advanced stages of epithelial ovarian cancers (EOCs) and correlate the expression with clinicopathological features.
  • METHODS: The expression of MUC1 was examined on frozen tissue sections from primary EOC (n=42), the matched metastatic lesions (n=30) and paraffin-embedded tissue sections from primary EOC (n=60), normal ovarian tissues (n=20) using immunohistochemistry (IHC) by monoclonal antibody (MAb) C595.
  • RESULTS: The expression of MUC1 was found in 92% (39/42) of EOC and 90% (27/30) of the matched metastatic lesions in frozen tissue sections respectively while the expression of MUC1 was found in 95% (57/60) of EOC and 5% (1/20) of normal ovarian tissues in paraffin-embedded sections respectively.
  • CONCLUSIONS: MUC1 is overexpressed in above 90% of late stage of EOC and of metastatic lesions but not in normal ovarian tissues, and the high expression of MUC1 is correlated with EOC progression.
  • MUC1 antigen may be a useful therapeutic target to prevent the development of incurable, recurrent metastatic EOC.
  • [MeSH-minor] Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Amino Acid Sequence. Antibodies, Monoclonal / chemistry. Antibodies, Monoclonal / immunology. Carcinoma, Endometrioid / metabolism. Carcinoma, Endometrioid / pathology. Cystadenocarcinoma, Serous / metabolism. Cystadenocarcinoma, Serous / pathology. Epithelial Cells / pathology. Female. Humans. Immunohistochemistry. Middle Aged. Molecular Sequence Data. Mucin-1. Paraffin Embedding


81. Nonaka M, Kataoka D, Yamamoto S, Horichi N, Ohgiya Y, Kushima M, Kunimura T, Takaba T: Outcome following surgery for primary lung cancer with interlobar pleural invasion. Surg Today; 2005;35(1):22-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The lymph node metastatic rate did not differ between the patients with and without interlobar P3.
  • The 5-year survival rate of the patients with interlobar P3 was lower in adenocarcinoma (39%) than in squamous cell carcinoma (69%, P < 0.01).
  • In adenocarcinoma, the survival rate for interlobar P3 was between the rates for T2 (53%) and T3 (13%) without interlobar P3, whereas in squamous cell carcinoma, the survival rate for interlobar P3 was between the rates for T1 (88%) and T2 (54%) without interlobar P3.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15622459.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


82. Singh A, Singh P, Sahni K, Shukla P, Shukla V, Pant NK: Non-small cell lung cancer presenting with choroidal metastasis as first sign and showing good response to chemotherapy alone: a case report. J Med Case Rep; 2010;4:185
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Metastatic tumors are the most common intra-ocular malignancies and choroid is by far the most common site for intra-ocular malignancies.
  • He was found to have an adenocarcinoma of the lung with choroidal metastasis as the first presenting sign.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Ophthalmol. 1973 Feb;89(2):97-9 [4683617.001]
  • [Cites] Arch Ophthalmol. 1974 Oct;92(4):276-86 [4412321.001]
  • [Cites] Am J Ophthalmol. 1982 Jan;93(1):102-6 [7065077.001]
  • [Cites] Am J Ophthalmol. 2003 Aug;136(2):264-71 [12888048.001]
  • (PMID = 20565905.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2916915
  •  go-up   go-down


83. Bralet MP, Paule B, Falissard B, Adam R, Guettier C: Immunohistochemical variability of epidermal growth factor receptor (EGFR) in liver metastases from colonic carcinomas. Histopathology; 2007 Jan;50(2):210-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND RESULTS: Forty patients had resection of colonic adenocarcinoma (27 with metastatic lymph nodes) and at least one partial hepatectomy (PH) for liver metastases; a second and a third PH were performed, respectively, in 14 and three patients; seven patients had tumour liver biopsy.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222249.001).
  • [ISSN] 0309-0167
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Validation Studies
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  •  go-up   go-down


84. Lavolé A, Wislez M, Antoine M, Mayaud C, Milleron B, Cadranel J: Lung cancer, a new challenge in the HIV-infected population. Lung Cancer; 2006 Jan;51(1):1-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • LC is diagnosed when it is locally advanced or metastatic (stages III-IV) in 75-90% of cases, as in patients with unknown HIV serostatus.
  • Adenocarcinoma is the most frequent histologic type.


85. Pawlik TM, Abdalla EK, Barnett CC, Ahmad SA, Cleary KR, Vauthey JN, Lee JE, Evans DB, Pisters PW: Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer. Arch Surg; 2005 Jun;140(6):584-9; discussion 589-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • HYPOTHESIS: The required sample size of a prospective randomized trial comparing standard pancreaticoduodenectomy with pancreaticoduodenectomy plus extended lymphadenectomy for pancreatic adenocarcinoma is prohibitively large, making such a trial infeasible.
  • PATIENTS: We identified 158 patients who underwent pancreaticoduodenectomy for pancreatic adenocarcinoma with separate pathologic analysis of second-echelon lymph nodes, defined as lymph nodes along the proximal hepatic artery and/or the great vessels.
  • MAIN OUTCOME MEASURES: To estimate the sample size required for a randomized trial, we devised a biostatistical model with the following assumptions: extended lymphadenectomy can benefit only patients who (1) actually have disease removed from second-echelon nodes, (2) have microscopically negative (R0) primary tumor resection margins, and (3) do not have visceral metastatic (M0) disease.
  • [MeSH-major] Adenocarcinoma / surgery. Lymph Node Excision. Pancreatic Neoplasms / surgery. Randomized Controlled Trials as Topic

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15967906.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Büchler MW, Friess H, Martignoni ME: Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg; 2008 Jul;12(7):1193-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIAL AND METHODS: Therefore, in this study, 227 consecutive patients with ductal adenocarcinoma of the pancreas were documented over an 18-month period regarding the prevalence of cachexia and its influence on perioperative morbidity and mortality with a special interest to postoperative weight gain and survival in a prospectively designed database and followed up.
  • Despite no significant differences in tumor size, lymph node status, and CA19-9 levels, the resection rate in patients with cachexia was reduced (77.8% vs. 48.9%) due to a higher rate of metastatic disease in patients with cachexia.
  • But tumor-related cachexia is not necessarily dependent on tumor size or load and that metastatic dedifferentiation of the tumor might be a critical step in the development of tumor-associated cachexia.

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30 [15661684.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2005 May;8(3):265-9 [15809528.001]
  • [Cites] World J Surg. 2003 Oct;27(10):1075-84 [12925907.001]
  • [Cites] Br J Surg. 2004 Nov;91(11):1410-27 [15499648.001]
  • [Cites] Ann Surg. 2002 Aug;236(2):137-48 [12170018.001]
  • [Cites] World J Gastroenterol. 2006 Jul 28;12(28):4466-72 [16874856.001]
  • [Cites] Support Care Cancer. 1999 Jul;7(4):233-43 [10423049.001]
  • [Cites] Surgery. 2004 Nov;136(5):1003-11 [15523393.001]
  • [Cites] Br J Surg. 2004 May;91(5):586-94 [15122610.001]
  • [Cites] Nat Clin Pract Oncol. 2005 Mar;2(3):158-65 [16264909.001]
  • [Cites] Br J Cancer. 2004 Mar 8;90(5):996-1002 [14997196.001]
  • [Cites] Curr Opin Clin Nutr Metab Care. 2003 Jul;6(4):407-12 [12806214.001]
  • [Cites] Clin Nutr. 2004 Apr;23(2):239-47 [15030964.001]
  • [Cites] Ther Umsch. 1996 May;53(5):401-7 [8685859.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2002 Feb;1(1):118-25 [14607639.001]
  • [Cites] Pancreas. 2006 Aug;33(2):111-8 [16868475.001]
  • [Cites] Magy Onkol. 2001;45(5):431-436 [12050692.001]
  • [Cites] Int J Cancer. 2001 Aug 1;93(3):380-3 [11433403.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(2):121-7 [9745076.001]
  • [Cites] Eur J Surg Oncol. 2007 Sep;33(7):817-23 [17331695.001]
  • [Cites] Nat Cell Biol. 2006 Dec;8(12):1369-75 [17128264.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):44-7; discussion 48 [11146775.001]
  • [Cites] World J Surg. 1999 Jun;23(6):584-8 [10227928.001]
  • [Cites] Br J Surg. 2000 Jul;87(7):883-9 [10931023.001]
  • [Cites] Br J Surg. 1995 Sep;82(9):1270-3 [7552016.001]
  • [Cites] Br J Cancer. 2001 Jul 20;85(2):297-302 [11461093.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] Nutrition. 2000 Oct;16(10):1013-4 [11054609.001]
  • [Cites] J Support Oncol. 2005 Sep-Oct;3(5):331-9 [16218255.001]
  • [Cites] Med Res Rev. 2001 Jan;21(1):83-101 [11135301.001]
  • [Cites] J Clin Oncol. 2006 Nov 20;24(33):5313-27 [17060676.001]
  • [Cites] Surg Clin North Am. 2001 Jun;81(3):595-610 [11459274.001]
  • [Cites] World J Surg. 1996 Mar-Apr;20(3):288-93; discussion 294 [8661833.001]
  • [Cites] Cancer Res. 1999 Sep 15;59(18):4493-501 [10493494.001]
  • [Cites] N Engl J Med. 2004 Mar 18;350(12):1200-10 [15028824.001]
  • [Cites] Dig Dis. 2003;21(3):198-213 [14571093.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1056-61 [16006800.001]
  • [Cites] Curr Oncol Rep. 2000 Jul;2(4):362-8 [11122866.001]
  • [Cites] Nat Rev Cancer. 2002 Nov;2(11):862-71 [12415256.001]
  • (PMID = 18347879.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


87. Lee DK, Park JH, Kim JH, Lee SJ, Jo MK, Gil MC, Song KH, Park JW: Progression of prostate cancer despite an extremely low serum level of prostate-specific antigen. Korean J Urol; 2010 May;51(5):358-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • He underwent laminectomy, posterior fixation, and epidural mass excision, and metastatic adenocarcinoma from the prostate was diagnosed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Clin Oncol. 2007 Dec;12(6):427-32 [18071861.001]
  • [Cites] Cancer. 2007 Jan 15;109(2):198-204 [17171704.001]
  • [Cites] J Urol. 1995 Dec;154(6):2128-31 [7500474.001]
  • [Cites] Urology. 2000 Sep 1;56(3):527-32 [10962338.001]
  • [Cites] Int J Urol. 2001 Jul;8(7):374-9 [11442659.001]
  • [Cites] Eur Urol. 2000 Sep;38(3):250-4 [10940696.001]
  • [Cites] Int Urol Nephrol. 2003;35(2):189-92 [15072491.001]
  • (PMID = 20495701.001).
  • [ISSN] 2005-6745
  • [Journal-full-title] Korean journal of urology
  • [ISO-abbreviation] Korean J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2873892
  • [Keywords] NOTNLM ; Disease progression / Multiple organ failure / Neoplasm metastasis / Prostate-specific antigen / Prostatic neoplasms
  •  go-up   go-down


88. Duffy A, Shia J, Klimstra D, Temple L, O'Reilly EM: Collision tumor of the large bowel in the context of advanced pregnancy and ulcerative colitis. Clin Colorectal Cancer; 2008 Nov;7(6):402-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A woman aged 33 years, during week 30 of pregnancy, presented with metastatic, high-grade neuroendocrine cancer.
  • Investigation revealed a collision-type primary tumor of the large bowel, containing adenocarcinoma and neuroendocrine elements.


89. Jones GE, Strauss DC, Forshaw MJ, Deere H, Mahedeva U, Mason RC: Breast cancer metastasis to the stomach may mimic primary gastric cancer: report of two cases and review of literature. World J Surg Oncol; 2007;5:75
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE PRESENTATIONS: The first patient, a 51 year old woman, developed an apparently localised signet-ring gastric adenocarcinoma 3 years after treatment for lobular breast cancer with no clinical evidence of recurrence.
  • Immunohistochemistry for Gross Cystic Disease Fluid Protein was positive, suggesting metastatic breast cancer.
  • The second patient, a 61 year old woman, developed a proximal gastric signet-ring adenocarcinoma 14 years after initial treatment for breast cancer which had subsequently recurred with bony and pleural metastases.

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Endoscopy. 2004 Jun;36(6):543-50 [15202052.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Sep;31(3):701-13 [12481726.001]
  • [Cites] Am J Dig Dis. 1972 Oct;17(10):881-6 [5073677.001]
  • [Cites] J Biol Chem. 1973 Aug 25;248(16):5736-41 [4723913.001]
  • [Cites] Am J Dig Dis. 1975 Oct;20(10):903-13 [1190198.001]
  • [Cites] Ann Surg. 1977 Mar;185(3):279-85 [843124.001]
  • [Cites] Mayo Clin Proc. 1980 Dec;55(12):747-53 [6261047.001]
  • [Cites] Am J Pathol. 1983 Feb;110(2):105-12 [6130702.001]
  • [Cites] Hum Pathol. 1989 Mar;20(3):281-7 [2542151.001]
  • [Cites] Gastrointest Endosc. 1992 Mar-Apr;38(2):130-5 [1568608.001]
  • [Cites] Surg Today. 1992;22(5):421-5 [1421863.001]
  • [Cites] Gastrointest Endosc. 1993 Jan-Feb;39(1):103-4 [8267696.001]
  • [Cites] Mod Pathol. 1993 Sep;6(5):516-20 [8248106.001]
  • [Cites] J Korean Med Sci. 1997 Jun;12(3):256-61 [9250925.001]
  • [Cites] Am J Gastroenterol. 1998 Jan;93(1):111-4 [9448188.001]
  • [Cites] Endoscopy. 1998 Nov;30(9):800-4 [9932762.001]
  • [Cites] Radiographics. 2004 Nov-Dec;24(6):1561-73 [15537965.001]
  • [Cites] Histopathology. 2005 Feb;46(2):153-7 [15693887.001]
  • [Cites] Arch Pathol Lab Med. 2005 Mar;129(3):338-47 [15737028.001]
  • [Cites] Onkologie. 2005 May;28(5):270-2 [15867484.001]
  • [Cites] Ann Surg Oncol. 2005 Nov;12(11):886-94 [16177864.001]
  • [Cites] Rev Gastroenterol Disord. 2006 Winter;6(1):1-12 [16520707.001]
  • [Cites] APMIS. 2006 Oct;114(10):712-9 [17004974.001]
  • [Cites] World J Gastroenterol. 2006 Dec 7;12(45):7326-8 [17143949.001]
  • [Cites] Am J Clin Pathol. 2007 Jan;127(1):103-13 [17145637.001]
  • [Cites] Lancet Oncol. 2007 Jan;8(1):55-62 [17196511.001]
  • [Cites] AJR Am J Roentgenol. 2000 Sep;175(3):795-800 [10954469.001]
  • [Cites] Cancer. 2000 Dec 1;89(11):2214-21 [11147591.001]
  • [Cites] Endoscopy. 2001 Jun;33(6):507-10 [11437044.001]
  • [Cites] J Gastrointest Surg. 2002 Jul-Aug;6(4):614-6 [12127129.001]
  • [Cites] Am J Dig Dis. 1968 Oct;13(10):868-73 [5303029.001]
  • (PMID = 17620117.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 32
  • [Other-IDs] NLM/ PMC1937002
  • [General-notes] NLM/ Original DateCompleted: 20070810
  •  go-up   go-down


91. Cox MC, Low J, Lee J, Walshe J, Denduluri N, Berman A, Permenter MG, Petros WP, Price DK, Figg WD, Sparreboom A, Swain SM: Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel. Clin Cancer Res; 2006 Aug 1;12(15):4636-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: Women with metastatic breast cancer were treated with docetaxel (30 mg/m(2)) given weekly for 3 of 4 weeks.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Agents / pharmacokinetics. Breast Neoplasms / drug therapy. Garlic. Taxoids / pharmacokinetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16899612.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Taxoids; 15H5577CQD / docetaxel; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.14.1 / CYP3A5 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A
  •  go-up   go-down


92. Tseleni-Balafouta S, Gakiopoulou H, Fanourakis G, Voutsinas G, Litsiou H, Sozopoulos E, Balafoutas D, Patsouris E: Fibrillin expression and localization in various types of carcinomas of the thyroid gland. Mod Pathol; 2006 May;19(5):695-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to investigate fibrillin-1 expression in thyroid carcinomas at mRNA and protein level, since ECM proteins are suggested to be of great importance for the metastatic potential of carcinomas.
  • [MeSH-major] Adenocarcinoma, Follicular / pathology. Carcinoma, Medullary / pathology. Carcinoma, Papillary / pathology. Microfilament Proteins / genetics. Thyroid Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16528372.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Microfilament Proteins; 0 / RNA, Messenger; 0 / fibrillin
  •  go-up   go-down


93. Van Putte BP, Hendriks JM, Romijn S, Pauwels B, Vermorken JB, Van Schil PE: Combination chemotherapy with gemcitabine with isolated lung perfusion for the treatment of pulmonary metastases. J Thorac Cardiovasc Surg; 2005 Jul;130(1):125-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vivo, left pulmonary metastases were induced in Wag/Rij rats by means of intravenous injection of CC531s adenocarcinoma cells.
  • Death by means of metastatic disease was the end point.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Cancer, Regional Perfusion. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Lung Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15999051.001).
  • [ISSN] 0022-5223
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Antineoplastic Agents, Alkylating; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; Q41OR9510P / Melphalan
  •  go-up   go-down


94. Yamashita M, Ino A, Kawabata K, Sakurai F, Mizuguchi H: Expression of coxsackie and adenovirus receptor reduces the lung metastatic potential of murine tumor cells. Int J Cancer; 2007 Oct 15;121(8):1690-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of coxsackie and adenovirus receptor reduces the lung metastatic potential of murine tumor cells.
  • In the present study, we examined CAR's role in tumor metastasis using a B16 melanoma and CT26 colon adenocarcinoma model of experimental metastasis.
  • Thus, CAR expression likely acts as a metastatic suppressor.
  • [MeSH-major] Adenocarcinoma / secondary. Colonic Neoplasms / secondary. Lung Neoplasms / secondary. Melanoma, Experimental / secondary. Receptors, Virus / metabolism

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17546646.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CLMP protein, mouse; 0 / Coxsackie and Adenovirus Receptor-Like Membrane Protein; 0 / Integrins; 0 / Receptors, Virus
  •  go-up   go-down


95. Stern AW, Velguth KE, D'Agostino J: Metastatic ductal adenocarcinoma in a Western Hognose snake (Heterodon nasicus). J Zoo Wildl Med; 2010 Jun;41(2):320-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic ductal adenocarcinoma in a Western Hognose snake (Heterodon nasicus).
  • Histologically, the mass was composed of tubules of columnar to flattened neoplastic cells with an abundant stroma and moderate cellular atypia consistent with a scirrhous adenocarcinoma, likely ductal in origin, given the location of the neoplastic mass.
  • Necropsy and histopathologic examination confirmed metastasis of the previously removed adenocarcinoma to the liver, right kidney, and large intestine.
  • [MeSH-major] Adenocarcinoma / veterinary. Snakes

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20597225.001).
  • [ISSN] 1042-7260
  • [Journal-full-title] Journal of zoo and wildlife medicine : official publication of the American Association of Zoo Veterinarians
  • [ISO-abbreviation] J. Zoo Wildl. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Jones HP, Wang YC, Aldridge B, Weiss JM: Lung and splenic B cells facilitate diverse effects on in vitro measures of antitumor immune responses. Cancer Immun; 2008;8:4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In vitro measures of immune responsiveness toward tumors provide relevant information regarding the prevention and metastatic potential of cancer.
  • In the current study, we determined the effect of B cells on antitumor cellular responses against a lung metastatic tumor, MADB106.
  • [MeSH-major] Adenocarcinoma / secondary. B-Lymphocytes / immunology. Immunologic Surveillance. Lung Neoplasms / immunology. Neoplasms, Experimental / immunology. Spleen / immunology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2000 Jun;9(6):609-17 [10868697.001]
  • [Cites] Expert Rev Vaccines. 2007 Apr;6(2):267-83 [17408375.001]
  • [Cites] Eur J Immunol. 2001 Jun;31(6):1720-7 [11385616.001]
  • [Cites] J Immunol. 2001 Oct 15;167(8):4518-26 [11591779.001]
  • [Cites] J Biol Chem. 2002 Mar 8;277(10):7766-75 [11726649.001]
  • [Cites] J Immunol. 2002 May 1;168(9):4472-9 [11970991.001]
  • [Cites] Semin Oncol. 2002 Jun;29(3 Suppl 7):5-11 [12068382.001]
  • [Cites] J Leukoc Biol. 2002 Aug;72(2):305-11 [12149421.001]
  • [Cites] Blood. 2002 Sep 1;100(5):1728-33 [12176894.001]
  • [Cites] Nat Immunol. 2002 Sep;3(9):867-74 [12154358.001]
  • [Cites] J Immunol. 2002 Oct 1;169(7):3676-85 [12244160.001]
  • [Cites] J Immunol. 2004 Jan 15;172(2):803-11 [14707050.001]
  • [Cites] J Immunol. 1985 Apr;134(4):2783-9 [3871818.001]
  • [Cites] J Immunol. 1989 Feb 15;142(4):1095-101 [2492576.001]
  • [Cites] Infect Immun. 1991 Oct;59(10):3715-21 [1894371.001]
  • [Cites] Immunol Today. 1994 Jul;15(7):321-31 [7522010.001]
  • [Cites] J Immunol. 1995 Jan 1;154(1):97-105 [7527824.001]
  • [Cites] Cancer Res. 1995 Jul 1;55(13):2730-3 [7540948.001]
  • [Cites] Cell Immunol. 1995 Oct 15;165(2):217-24 [7553886.001]
  • [Cites] Cancer Immunol Immunother. 1995 Dec;41(6):339-47 [8635191.001]
  • [Cites] Immunity. 1996 Oct;5(4):311-7 [8885864.001]
  • [Cites] Immunol Rev. 1996 Oct;153:5-26 [9010717.001]
  • [Cites] Nat Med. 1998 May;4(5):627-30 [9585241.001]
  • [Cites] Semin Immunol. 1999 Feb;11(1):1-2 [9950747.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1080-9 [10070966.001]
  • [Cites] Scand J Immunol. 1999 Jun;49(6):633-40 [10354375.001]
  • [Cites] J Immunol. 1999 Jun 15;162(12):7198-207 [10358166.001]
  • [Cites] Pathobiology. 1999 May-Jun;67(3):123-8 [10394132.001]
  • [Cites] Int J Cancer. 2006 Jan 15;118(2):388-95 [16049975.001]
  • [Cites] J Clin Invest. 2006 Nov;116(11):2901-13 [17024246.001]
  • [Cites] Cell Motil Cytoskeleton. 2007 Mar;64(3):186-98 [17183544.001]
  • [Cites] Cytokine Growth Factor Rev. 2007 Feb-Apr;18(1-2):171-82 [17329145.001]
  • [Cites] Hum Immunol. 2000 Aug;61(8):721-8 [10980383.001]
  • (PMID = 18281925.001).
  • [ISSN] 1424-9634
  • [Journal-full-title] Cancer immunity
  • [ISO-abbreviation] Cancer Immun.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD80; 0 / Antigens, CD86; 82115-62-6 / Interferon-gamma
  • [Other-IDs] NLM/ PMC2935774
  •  go-up   go-down


97. Choi IK, Seo HY, Sung HJ, Park KH, Kim SJ, Oh SC, Seo JH, Choi CW, Kim BS, Shin SW, Kim YH, Kim JS: Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer. Med Oncol; 2007;24(1):33-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epirubicin, cisplatin, oral UFT, and leucovorin combination chemotherapy in advanced and metastatic esophageal cancer.
  • BACKGROUND: The purpose of treatment in patients with advanced and metastatic esophageal cancer is to improve symptoms and maintain quality of life.
  • Recently, the regimen including epirubicin, cisplatin, and 5-FU (ECF) has been used with protracted venous infusion (PVI), and has been reported to be an effective treatment for advanced and metastatic esophagogastric cancer.
  • Four patients had adenocarcinoma.
  • And this treatment might be more effective in adenocarcinoma of esophageal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Esophageal Neoplasms / drug therapy


98. Landmann RG, Wong WD, Hoepfl J, Shia J, Guillem JG, Temple LK, Paty PB, Weiser MR: Limitations of early rectal cancer nodal staging may explain failure after local excision. Dis Colon Rectum; 2007 Oct;50(10):1520-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endorectal ultrasound was more likely to overlook small metastatic lymph node deposits.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / ultrasonography. Endosonography. Neoplasm Staging / methods. Rectal Neoplasms / pathology. Rectal Neoplasms / ultrasonography

  • Genetic Alliance. consumer health - Rectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17674104.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


99. Figueras J, Torras J, Valls C, Llado L, Ramos E, Marti-Ragué J, Serrano T, Fabregat J: Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis Colon Rectum; 2007 Apr;50(4):478-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A total of 501 patients had 545 liver resections for metastatic colorectal cancer.
  • [MeSH-major] Adenocarcinoma / secondary. Adenocarcinoma / therapy. Colorectal Neoplasms / pathology. Hepatectomy. Liver Neoplasms / secondary. Liver Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17279302.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


100. Ohtsubo K, Watanabe H, Yamada T, Tsuchiyama T, Mouri H, Yamashita K, Yasumoto K, Ikeda H, Nakanuma Y, Yano S: Cancer of unknown primary site in which tumor marker-oriented chemotherapy was effective and pancreatic cancer was finally confirmed at autopsy. Intern Med; 2009;48(18):1651-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Although a primary lesion was not confirmed, we planned to perform tumor marker-oriented chemotherapy because pancreatic cancer was suspected as the primary lesion based on tumor markers and pathological findings from metastatic lymph node.
  • Microscopic examination at autopsy revealed poorly differentiated adenocarcinoma in the pancreatic head, although a pancreatic mass was not clear macroscopically.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Adenocarcinoma / secondary. Antigens, Neoplasm / metabolism. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Autopsy. Biomarkers, Tumor / metabolism. Cisplatin / administration & dosage. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19755768.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DU-PAN-2 antigen, human; 0 / pancreatic associated antigen, SPan-1; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down






Advertisement